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A B S T R A C T
Background
Breast-conserving therapy for women with breast cancer consists of local excision of the tumour (achieving clear margins) followed by
radiotherapy (RT). RT is given to sterilize tumour cells that may remain after surgery to decrease the risk of local tumour recurrence.
Most true recurrences occur in the same quadrant as the original tumour. Whole breast radiotherapy (WBRT) may not protect against
the development of a new primary cancer developing in other quadrants of the breast. In this Cochrane review, we investigated the
delivery of radiation to a limited volume of the breast around the tumour bed (partial breast irradiation (PBI)) sometimes with a
shortened treatment duration (accelerated partial breast irradiation (APBI)).
Objectives
To determine whether PBI/APBI is equivalent to or better than conventional or hypo-fractionated WBRT after breast-conserving
therapy for early-stage breast cancer.
Search methods
We searched the Cochrane Breast Cancer Group Specialized Register (4 May 2015), the Cochrane Central Register of Controlled
Trials (CENTRAL) (2015, Issue 5), MEDLINE (January 1966 to 4 May 2015), EMBASE (1980 to 4 May 2015), CINAHL (4 May
2015) and Current Contents (4 May 2015). We searched the International Standard Randomised Controlled Trial Number Register
(5 May 2015), the World Health Organization’s International Clinical Trials Registry Platform (4 May 2015) and ClinicalTrials.gov
(17 June 2015). We searched for grey literature: OpenGrey (17 June 2015), reference lists of articles, several conference proceedings
and published abstracts, and applied no language restrictions.
Selection criteria
Randomized controlled trials (RCTs) without confounding, that evaluated conservative surgery plus PBI/APBI versus conservative
surgery plus WBRT. Published and unpublished trials were eligible.
Data collection and analysis
Two review authors (BH and ML) performed data extraction and used Cochrane’s ’Risk of bias’ tool, and resolved any disagreements
through discussion. We entered data into Review Manager 5 for analysis.
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Main results
We included seven RCTs and studied 7586 women of the 8955 enrolled.
Local recurrence-free survival appeared worse for women receiving PBI/APBI compared to WBRT (hazard ratio (HR) 1.62, 95%
confidence interval (CI) 1.11 to 2.35; six studies, 6820 participants, low-quality evidence). Cosmesis (physician-reported) appeared
worse with PBI/APBI (odds ratio (OR) 1.51, 95% CI 1.17 to 1.95, five studies, 1720 participants, low-quality evidence). Overall
survival did not differ with PBI/APBI (HR 0.90, 95% CI 0.74 to 1.09, five studies, 6718 participants, high-quality evidence).
Late radiation toxicity (subcutaneous fibrosis) appeared worse with PBI/APBI (OR 6.58, 95% CI 3.08 to 14.06, one study, 766
participants, moderate-quality evidence). Acute skin toxicity appeared reduced with PBI/APBI (OR 0.04, 95% CI 0.02 to 0.09, two
studies, 608 participants). Telangiectasia (OR 26.56, 95% CI 3.59 to 196.51, 1 study, 766 participants) and radiological fat necrosis
(OR 1.58, 95% CI 1.02 to 2.43, three studies, 1319 participants) appeared worse with PBI/APBI. Late skin toxicity (OR 0.21, 95%
CI 0.01 to 4.39, two studies, 608 participants) and breast pain (OR 2.17, 95% CI 0.56 to 8.44, one study, 766 participants) appeared
not to differ with PBI/APBI.
’Elsewhere primaries’ (new primaries in the ipsilateral breast) appeared more frequent with PBI/APBI (OR 3.97, 95% CI 1.51 to 10.41,
three studies, 3009 participants).
We found no clear evidence of a difference for the comparison of PBI/APBI with WBRT for the outcomes of: cause-specific survival
(HR 1.08, 95% CI 0.73 to 1.58, five studies, 6718 participants, moderate-quality evidence), distant metastasis-free survival (HR 0.94,
95% CI 0.65 to 1.37, four studies, 3267 participants, moderate-quality evidence), relapse-free survival (HR 1.36, 95% CI 0.88 to 2.09,
three studies, 3811 participants), loco-regional recurrence-free survival (HR 1.80, 95% CI 1.00 to 3.25, two studies, 3553 participants)
or mastectomy rates (OR 1.20, 95% CI 0.77 to 1.87, three studies, 4817 participants, low-quality evidence). Compliance was met:
more than 90% of the women in all studies received the RT they were assigned to receive. We found no data for the outcomes of costs,
quality of life or consumer preference.
Authors’ conclusions
It appeared that local recurrence and ’elsewhere primaries’ (new primaries in the ipsilateral breast) are increased with PBI/APBI (the
difference was small), but we found no evidence of detriment to other oncological outcomes. It appeared that cosmetic outcomes and
some late effects were worse with PBI/APBI but its use was associated with less acute skin toxicity. The limitations of the data currently
available mean that we cannot make definitive conclusions about the efficacy and safety or ways to deliver of PBI/APBI. We await
completion of ongoing trials.
P L A I N L A N G U A G E S U M M A R Y
Partial breast irradiation for early breast cancer
What is the issue?
Women with early breast cancer who choose to keep their breast need to have radiotherapy (RT) as well as surgery to remove the cancer
to make sure it does not regrow in the breast. RT is treatment with high energy x-rays. Having RT for breast cancer usually means 25
to 30 visits to the RT department, five times per week.
If breast cancer does regrow in the same breast (called local recurrence), it tends to come back in the area it was removed from. Women
can also grow a new cancer (new ’elsewhere primary’) in another part of the same breast. We are not sure if the RT given to stop cancer
regrowth where the first cancer was does stop the growth of ’elsewhere primaries’.
Breast cancer is the most common cancer that women get. When women choose to keep their breast, it is important that they are
happy with how it looks after treatment (cosmesis).
Why does it matter?
We always want to treat the smallest area we can with RT because this means fewer side effects. Treating only part of the breast could
mean that RT might be able to be used again in another part of the same breast if needed. New ways of giving RT mean that treating
part of the breast can be done with fewer treatments. This is likely to be easier for women and cost less money.
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We asked if giving RT to part of the breast (called partial breast irradiation (PBI)) is as good as giving RT to the whole breast. It would
need to control the cancer as well as giving RT to the whole breast does. It would also be important that the PBI gives about the same
side effects and breast appearance as treating the whole breast.
We found seven studies, which involved 7586 women. Our evidence is current to May 2015. Local recurrence was rare, but more
common with PBI (low-quality evidence) and the breast appearance (scored by doctors) was worse with PBI (low-quality evidence).
Survival did not differ (high-quality evidence). Scarring in the breast was worse with PBI (moderate-quality evidence). The same
number of women died of breast cancer with either treatment (moderate-quality evidence). The same number of women developed
spread of breast cancer around their body with either treatment (moderate-quality evidence). There appeared to be the same number of
women who eventually needed the breast removed (mastectomy) after both treatments. Mastectomy could happen because of cancer
regrowth in the breast or bad side effects (low-quality evidence).
This means that at the moment, PBI does not give the same cancer control in the breast as treating the whole breast, but the difference
was small. It may cause worse side effects. There are five big ongoing studies that will be important to answer this question. We hope
to have a clearer answer in the next update of this review.
3Partial breast irradiation for early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
PBI/ APBI for women with early breast cancer
Patient or population: women with early breast cancer
Setting: radiotherapy centres
Intervention: PBI/ APBI
Comparison: whole breast radiotherapy (WBRT)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with WBRT Risk with PBI/ APBI
Local recurrence-f ree
survival at 5 years
Study populat ion HR 1.62
(1.11 to 2.35)
6820
(6 RCTs)
⊕⊕©©
Low 3,4,5,6
-
10 per 10001 16 per 1000
(11 to 23)
Cosmesis assessed
with 4-point scale
Follow-up: range 29-
122 months
Study populat ion OR 1.51
(1.17 to 1.95)
1720
(5 RCTs)
⊕⊕©©
Low 6,7,8,9
Cosmesis was as-
sessed using a 4-
point scale. We re-
ported those women
with poor/ fair cosme-
sis at f inal review
150 per 1000 218 per 1000
(174 to 272)
Late radiotherapy toxic-
ity (subcutaneous f ibro-
sis)
Follow-up: median 36
months
Study populat ion OR 6.58
(3.08 to 14.06)
766
(1 RCT)
⊕⊕⊕©
Moderate 5,7,10
Assessed using Na-
t ional Cancer Inst itute
3-point scale, events
were def ined as: Grade
II or higher toxicity
Physician assessors, at
3 years’ follow-up
22 per 1000 128 per 1000
(64 to 239)
Cause-specif ic survival
at 5 years
Study populat ion HR 1.08
(0.73 to 1.58)
6718
(5 RCTs)
⊕⊕⊕©
Moderate 5,11
-
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20 per 10002 22 per 1000
(15 to 32)
Distant metastasis-f ree
survival at 5 years
Study populat ion HR 0.94
(0.65 to 1.37)
3267
(4 RCTs)
⊕⊕⊕©
Moderate 5,12
-
33 per 10002 31 per 1000
(21 to 44)
Mastectomy rate
Follow-up: range 29-
122 months
Study populat ion OR 1.20
(0.77 to 1.87)
4817
(3 RCTs)
⊕⊕©©
Low 5,11,13
Mastectomy rate re-
f lected both local recur-
rence and adverse cos-
metic outcome
15 per 1000 18 per 1000
(12 to 28)
Mortality
(follow-up: 5 years sur-
vival)
Study populat ion HR 0.90
(0.74 to 1.09)
6718
(5 RCTs)
⊕⊕⊕⊕
High
Survival
advantage f rom radio-
therapy for breast can-
cer is not apparent be-
fore 15 years’ follow-up
(EBCTCG 2011)
51 per 10002 46 per 1000
(38 to 55)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; HR: hazard rat io; OR: odds rat io; RCT: randomized controlled trial.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 The baseline risk for the control group was calculated at the 5-year t ime point f rom 5 studies.
2 The baseline risks for the control groups were calculated at the 5-year t ime point f rom 4 studies.
3 There was considerable clinical heterogeneity with respect to radiotherapy dose, technique and use of quality assurance
procedures. However, the techniques employed delivered a dose that was the same or higher in the accelerated part ial breast
irradiat ion arm than the whole breast radiotherapy arm, which should mean the local recurrence-f ree survival is better or at
least the same.
4 38% of the women contribut ing to this outcome came f rom a study deemed at high risk of bias for short follow-up.5
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5 There were fewer than 300 events.
6 Conf idence intervals did not exclude both clinically important and clinically unimportant harms.
7 Optimum sample size was not met, therefore downgraded.
8 There was evidence of considerable heterogeneity on stat ist ical test ing (I2 = 71%; P value < 0.00001).
9 Less than 30% of events came f rom studies deemed at high risk of bias for subject ive outcomes.
10 Test ing for heterogeneity was not appropriate, given that there was only one study contribut ing to this outcome.
11 Conf idence intervals did not exclude either clinically signif icant benef its or harms.
12 Conf idence intervals did not exclude the possibility of clinically signif icant harms.
13 One of the two included studies had median follow-up of 29 months, which was too short to report this outcome.
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B A C K G R O U N D
Description of the condition
Breast cancer is the most common cancer occurring in women.
One in eight women living in theUS and theUKhas a lifetime risk
of being diagnosed with breast cancer; while one in nine women
living in Australia are at risk (AIHW 2012; Howlader 2009; ONS
2010). Breast cancer is the second most common cause of cancer
death in women.
Historically, mastectomy was the recommended therapeutic op-
tion for all stages of breast cancer. However, large randomised con-
trolled trials (RCTs) demonstrated equivalent survival for women
with early-stage disease (Stages I, II) whether they were treated
with breast-conserving therapy or mastectomy (EBCTCG 1995;
Fisher 1995; Fisher 2002; Jacobson 1995; Poggi 2003; vanDongen
2000; Veronesi 1995; Veronesi 2002). Consequently, breast con-
servation has become the preferred management option for these
women.
Breast-conserving therapy consists of local excision of the tumour
(achieving clear margins) followed by radiotherapy (RT). RT is
given to sterilize tumour cells that may remain after surgery. This
practice is supported by data from detailed pathological examina-
tion of mastectomy specimens where residual tumour was found
more than 2 cm from the original tumour in 41% of participants
(Holland 1985). Conventional RT delivers 45 to 50 Gray (Gy) to
the whole breast over five weeks frequently followed by a boost to
the tumour bed (the most likely site of residual tumour cells) of 10
to 16 Gy over one to two weeks. This prolonged duration of treat-
ment negatively impacts on quality of life (Whelan 2000), and
contributes to the higher mastectomy rates observed in women
residing in rural and remote areas who wish to avoid being away
from home and family for extended periods (Schroen 2005).
Hypofractionated whole breast radiotherapy (WBRT) regimens,
in which 40 to 42.5 Gy is delivered to the whole breast over three
to four weeks using a larger radiation dose with each treatment
have been investigated. Compared to conventional WBRT, hy-
pofractionated WBRT results in no difference in breast recurrence
rates at five and 10 years, no difference in overall survival (OS) and
an improvement in cosmetic outcomes (START 2008; START B
2008; Whelan 2002).
RCTs have shown that the addition of conventional or hypofrac-
tionated WBRT to local excision decreases ipsilateral breast (same
breast) recurrence rates from 30% to 40% (Fisher 1995; Fisher
2002; Freeman 1981; Lagios 1983;Montgomery 1978) to 10% to
20% with 10 to 15 years of follow-up (Fisher 1995; Fisher 2002).
Modern breast-conserving therapy with postoperative WBRT
achieves local control rates of 3.3% to 3.4% at five years and 5.2%
to 6.7% at 10 years (Haviland 2013). With careful patient selec-
tion (aged 65 years or greater, T1-2 tumours, tumour not greater
than 3 cm, margin negative, oestrogen receptor positive and all re-
ceiving tamoxifen), surgery alone can achieve local recurrence rates
of 4.1% at five years (Kunkler 2015). An ipsilateral recurrence can
either be a true recurrence of the original cancer (typically arising
in the same quadrant as the original tumour and known as lo-
cal recurrence) or a second primary tumour developing elsewhere
in that same breast. Studies evaluating ipsilateral breast tumour
recurrence patterns showed that new primaries increasingly con-
tribute to the rate of recurrence after five to eight years while true
recurrence rates stabilize (Krauss 2004; Smith 2000). If WBRT
was successful in preventing the recurrence of new primary can-
cers, the rate of such cancers in the treated breast should be lower
than the rate of development of cancers in the other breast (con-
tralateral breast cancer). Studies of ipsilateral breast tumour recur-
rence patterns have not found this (Krauss 2004; Smith 2000).
Furthermore, studies examining primary and re-excision patho-
logical specimens removed at the time of breast-conserving surgery
revealed residual tumour 15 mm or less from the primary tumour
in 91% of the specimens (Wallner 2004).
Thus, as most true recurrences occur in the same quadrant as
the original tumour and as WBRT does not appear to protect
against the development of new primary cancer, investigators are
examining the role of partial breast irradiation (PBI).
Description of the intervention
PBI (also known as less than WBRT) refers to irradiation of a
limited volume of breast tissue around the tumour bed. It may be
achieved by any of the following techniques.
1. Intracavitary brachytherapy or MammoSite® (applying
radioactive sources directly into the cavity left after surgical
removal of the tumour either at the time of surgery or at a later
date, the latter requiring a second procedure).
2. Interstitial brachytherapy (inserting catheters into the
surgical cavity and surrounding tissue to temporarily deliver
radioactive sources).
3. Intra-operative techniques using electrons or x-rays at 50
kVp (using a dedicated machine to deliver a very localized
radiation dose to the surgical cavity in the operating room or by
moving the person with an open wound to the radiation
machine, which may be in a different part of the hospital).
4. External beam radiotherapy (EBRT) using either three-
dimensional conformal radiotherapy (3D-CRT) (EBRT
delivered in the postoperative setting to a volume of breast tissue
around the tumour cavity using a standard linear accelerator in a
radiation oncology department) or other methods.
Conventional RT typically delivers a radiation dose of 2 Gy with
each treatment. Some PBI techniques deliver a larger than stan-
dard dose of radiation with each treatment, allowing the overall
duration of treatment to be shortened. This is termed accelerated
partial breast irradiation (APBI).
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How the intervention might work
PBI/APBI will only be of benefit if it confers the same local control
benefit as standard WBRT with acceptable toxicity and cosmesis.
Currently, some authorities consider PBI/APBI to be an exper-
imental therapy (Clinical Evidence). The National Comprehen-
sive Cancer Network (NCCN) state, “Preliminary studies of APBI
suggest rates of local control in patients with early-stage breast
cancer may be comparable to those treated with WBRT. Follow-
up, however is limited and studies are ongoing” (NCCN). Be-
cause this technique has been widely adopted outside the context
of clinical trials, published guidelines exist that identify women
with early breast cancer for whom this technique may be safe. For
those women ineligible for a trial, carefully selected women with
early breast cancer may be offered PBI/APBI (Bellon 2011; Polgár
2010; Smith 2009).
PBI/APBI has a number of potential advantages including:
1. a reduction in treatment-related toxicities, as a smaller
volume of breast tissue is irradiated;
2. increased utilization of breast conservation;
3. a reduction in RT waiting times; a reduction in the overall
treatment duration of a common malignancy has the potential to
substantially impact on RT waiting times in countries with
strained resources (including the UK, Canada, Australia and
New Zealand);
4. a greater chance of preserving the breast should a recurrence
occur elsewhere in the breast;
5. easier integration with chemotherapy schedules because RT
time will be shorter, thus avoiding delays.
PBI/APBI has a number of potential disadvantages including:
1. an increased risk of local recurrence due to geographic miss.
This is either because treatment was delivered before full
pathological examination was obtained or because of difficulty in
reproducing the target volume (the tissue that needed to be
treated with RT) daily;
2. increased late toxicity. The late effects of radiation are
dependent on the dose of radiation given at each treatment and,
as PBI/APBI delivers a large radiation dose per fraction, late
toxicity may be increased with resultant poor cosmetic outcome
or breast appearance (cosmesis);
3. more patient inconvenience as some techniques may require
a second anaesthetic or a further invasive procedure;
4. a number of techniques (e.g. interstitial and intracavitary
brachytherapy) require operator expertise and specialized
equipment that may not be available in all centres;
5. invasive techniques of delivering PBI/APBI (e.g. interstitial
and intracavitary brachytherapy) may be associated with toxicity
such as infection and delays in wound healing. Scarring post-
insertion of interstitial brachytherapy catheters can negatively
impact on cosmetic appearance.
Why it is important to do this review
PBI/APBI has the potential to change the pattern of practice for a
common malignancy and thereby impact on resource utilization,
patient satisfaction and quality of life. However, as PBI/APBI is
currently an experimental therapy, it must be thoroughly evalu-
ated before being adopted as the new standard of care for early-
stage breast cancer. PBI/APBI can be recommended if it is as effec-
tive or better than conventional or hypofractionated WBRT for
cancer-related outcomes (local relapse-free survival (LR-FS), sur-
vival, breast cancer-specific survival and metastasis-free survival)
as well as patient-orientated outcomes (cosmesis, quality of life
and consumer preference). We found one systematic review that
concluded, “The data on PBI/APBI compared to whole-breast ir-
radiation are insufficient to draw any conclusions about the rela-
tive effectiveness of these modalities” (BlueCross BlueShield). The
fact that the benefit versus risk profile of PBI/APBI is currently
unknown makes it an ideal topic for a systematic review.
O B J E C T I V E S
To determine whether PBI/APBI is equivalent to or better than
conventional or hypofractionated WBRT after breast-conserving
therapy for early-stage breast cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) evaluating conservative
surgery plus PBI/APBI versus conservative surgery plus WBRT.
The comparisons had to be unconfounded (i.e. treatments given
to the randomized groups had to differ only in relation to the vol-
ume of the breast irradiated). Trials incorporating adjuvant treat-
ments, such as chemotherapy,monoclonal antibodies or hormonal
therapy, were eligible if the RCT applied these other treatments in
exactly the same way to both groups. Published and unpublished
studies were eligible.
We did not consider studies in which PBI was used as a boost
following conventional EBRT for inclusion.
Types of participants
Women with histologically confirmed early-stage breast can-
cer who had conservative surgery. Early breast cancer included
tumours classified as American Joint Committee on Cancer
8Partial breast irradiation for early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(AJCC) stage T1-2N0-1M0 (Fleming 1997). Surgery could in-
clude lumpectomy and wide local excision or quadrantectomy,
with or without axillary dissection, axillary sampling or sentinel
node biopsy. Women with a previous diagnosis of breast cancer
were not eligible for inclusion.
Types of interventions
Radiation delivered to the partial breast (PBI) and PBI using larger
than standard radiation dose per fraction such that the overall
treatment time was reduced (APBI). We considered any method
of PBI/APBI delivery including, but not limited to, intracavitary
brachytherapy or MammoSite®, interstitial brachytherapy, intra-
operative techniques such as electrons or x-rays at 50 kVp or EBRT
using either 3D-CRT or other methods. Conventional breast RT
is delivered to the whole breast with or without the supra-clavicu-
lar fossa and axilla, using standard fractionation (1.8 to 3.0 Gy per
fraction) to deliver a total of 40 to 61 Gy at the reference point.
Treatment could include a boost (using electrons, interstitial ther-
apy, EBRT or new techniques).
Types of outcome measures
Primary outcomes
1. Local recurrence-free survival (LR-FS) in the ipsilateral
breast. We defined local recurrence as a recurrence of the same
histological type of cancer within the same quadrant of the breast
as the primary cancer.
2. Cosmesis (cosmetic outcome or breast appearance).
Secondary outcomes
1. Overall survival (OS, time from date of randomization to
death from any cause, or number of deaths from any cause).
2. Toxicity (including acute and late effects of RT,
chemotherapy-related toxicity and surgical toxicity; individual
protocol-based definitions).
3. New primary tumours in ipsilateral breast, ’elsewhere
primary’. We defined a new primary as a lesion arising in a
quadrant of the breast that was different from the original cancer
or a tumour of a different histological subtype occurring
anywhere within the breast.
4. Cause-specific survival (C-SS, deaths due to breast cancer at
five years).
5. Distant metastasis-free survival (DM-FS, in isolation or at
the same time as local recurrence (the occurrence of metastases at
five years)).
6. Relapse-free survival (R-FS, length of time after treatment
during which no recurrence was found). Recurrence referred to
breast cancer in the ipsilateral breast or elsewhere in the body,
excluding a new breast cancer in the contralateral breast.
7. Loco-regional recurrence-free survival (L-RR-FS, comprised
local recurrence, “elsewhere” ipsilateral breast primaries (a new
primary cancer in the same breast) and regional nodal relapse).
8. Subsequent mastectomy (ipsilateral partial mastectomy,
modified radical mastectomy or radical mastectomy).
9. Compliance, defined as the number of women who
commenced treatment with PBI/APBI or conventional external
beam radiotherapy (EBRT) and completed the treatment course.
10. Costs (monetary costs of PBI versus EBRT) to women,
government and insurance companies.
11. Quality of life (using trial-specific instruments). The effects
of PBI/APBI and EBRT on global quality of life and the
physical, emotional and psychological domains.
12. Consumer preference, that is, did women prefer PBI/APBI
or WBRT given the advantages and disadvantages of each
approach.
Search methods for identification of studies
Electronic searches
Electronic databases
We searched the following databases:
1. the Cochrane Breast Cancer Group Specialized Register (4
May 2015). Details of search strategies used to identify studies
and the procedure used to code references are outlined in the
group’s module (Cochrane Breast Cancer Group). We extracted
studies on the specialized register with keywords ’early breast
cancer’, ’radiotherapy’, ’partial breast irradiation’, ’whole breast
irradiation’, ’whole breast radiotherapy’, ’brachytherapy’, ’high-
dose-rate brachytherapy’, ’accelerated partial breast irradiation’,
’tumour bed boost’, ’sole tumour bed irradiation’, ’MammoSite’,
’radiotherapy’, ’PBI’, ’APBI’ and ’interstitial brachytherapy’ for
consideration;
2. the Cochrane Central Register of Controlled Trials
(CENTRAL) (2015, Issue 3; Appendix 1);
3. MEDLINE (January 1966 to 4 May 2015; Appendix 2);
4. EMBASE (1980 to 4 May 2015; Appendix 3);
5. CINAHL (1981 to 4 May 2015; Appendix 4);
6. Current Contents (1998 to 4 May 2015; Appendix 5).
We modified the MEDLINE search strategy (Appendix 2) to
search the other databases, without language restrictions.
Unpublished literature
We searched following registers for ongoing clinical trials:
1. the International Standard Randomised Controlled Trial
Number Register (www.controlled-trials.com/isrctn) (5 May
2015);
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2. the World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) search portal (apps.who.int/
trialsearch/Default.aspx) (4 May, 2015; Appendix 6);
3. US clinical trials registry (www.clinicaltrials.gov) (17 June
2015; Appendix 7).
Grey literature
We checked OpenGrey (www.opengrey.eu/) (17 June 2015;
Appendix 8).
Searching other resources
We contacted researchers located from the grey literature and un-
published literature to ask if they were aware of any other trials
on this topic. We contacted the Barcelona authors on 15 Octo-
ber 2012 for more information. We contacted the IRMA authors
on 2 October 2012 and they supplied us with the trial protocol.
We contacted the authors of Polgár 2007 on 24 August 2013;
we gratefully received and incorporated data from the authors of
Polgár 2007 in November 2013.
Handsearching
We handsearched a number of conference proceedings and pub-
lished abstracts including:
1. Adjuvant Therapy for Primary Breast Cancer International
Conference (2001);
2. Primary Therapy of Early Breast Cancer (2001 and 2003);
3. 6th and 7th Nottingham International Breast Cancer
Meeting Conference Reports;
4. 23rd and 24th Congress of the International Association for
Breast Cancer Research;
5. 3rd and 4th Perspectives in Breast Cancer Conference
Reports;
6. 26th and 27th Annual San Antonio Breast Cancer
Symposium;
7. 4th European Breast Cancer Conference;
8. 94th and 95th American Association of Cancer Research;
9. American Society for Clinical Oncology (1995 to 2005);
10. European Society for Therapeutic and Radiation Oncology
(1990, 1993, 2000 to 2010, 2012);
11. 5th and 6th Milan Breast Cancer Conference;
12. Australian Breast Cancer Conference (2004);
13. 27th and 28th Annual Symposium of the American Society
of Breast Disease;
14. Centers for Disease Control and Prevention (CDC) Cancer
Conference (2003);
15. International Journal of Radiation Oncology Biology
Physics: proceedings of American Society for Radiation
Oncology (ASTRO) 2011 to 2015;
16. Radiotherapy and Oncology: Proceedings of World
Congress of Brachytherapy 2012;
17. American Society of Clinical Oncology (ASCO) from 1995
to 2010.
Data collection and analysis
Selection of studies
Three review authors (ML, BH and DF) checked the titles and
abstracts retrieved by the searches. Each review author indepen-
dently assessed the full text of the studies thought relevant to the
review and we resolved any differences in assessment by discus-
sion. We performed trial assessments with the results masked. In
cases where data were limited or information on trial methods was
limited, we requested further information from the trial authors.
Data extraction and management
Two review authors (ML and BH) performed data extraction and
resolved disagreements through discussion. We entered data into
Review Manager 5 for analysis (RevMan 2012). Where possi-
ble, we extracted data on tumour stage, nodal status, margin sta-
tus, receptor status, hormonal manipulation, treatment alloca-
tion and surgery performed. The information extracted on RT
included overall treatment time, radiation dose, dose per fraction
and method of PBI. We extracted outcome data on local recur-
rence, deaths (all-cause and breast cancer deaths), new ipsilateral
primaries, mastectomy rate, distant metastases, treatment-related
toxicity (including that related to acute and late effects of RT and
to surgery), cosmesis, costs of treatment, consumer preference and
quality of life.
We derived data for OS, LR-FS, DM-FS, disease-free survival and
C-SS from information in the text (ELIOT; Livi 2015; RAPID;
Rodriguez; TARGIT) and data received from trial authors (Polgár
2007). Trial authors of Polgár 2007 provided the HR, 95% CI
and P values, together with the number of events with further
follow-up.We used the spreadsheet developed byMatthew Sydes (
Tierney 2007) to deriveO-E (observedminus expected events) and
variance using the number of events,HRs, P values where available
or calculated using the Review Manager 5 calculator (RevMan
2012). Although there were data for loco-regional recurrence for
ELIOT, we did not include them in the analysis, because some
women were treated with regional nodal RT.
We converted the radiation doses to the equivalent dose in 2 Gy
fractions (EQD2 ) (Maciejewski 1986; Withers 1983), using the
formula: EQD2 = D [d + (alpha/beta/2 + alpha/beta)], where D
= total dose, d = dose per fraction and alpha/beta = 4 Gy (Owen
2006). This was to facilitate comparison of radiation doses given
at differing dose per fraction.
We plan to convert brachytherapy (radiation sources applied di-
rectly to the body) to the biological equivalent dose (BED) using
themethod of Stitt 1992 should it be necessary to pool brachyther-
apy data in future updates of this review.
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Studies reported global cosmetic outcome using the Harvard Cos-
metic Score (Polgár 2007; Livi 2015; Rodriguez), the European
Organization for Research and Treatment of Cancer (EORTC)
Cosmetic rating System for Breast Cancer) (Aaronson 1998;
RAPID), and a software program (TARGIT). These were all four-
point scales; the results were dichotomized into good/excellent and
fair/poor, with occurrence of fair/poor being counted as ’events’.
See Table 1.
One study reported telangiectasia (RAPID; using NCI CTCAE
Version 3.0; also a three-point scale): we recorded any women with
Grade 2 or higher toxicity as having events.
Three studies reported radiological or asymptomatic fat necrosis
(ELIOT; Polgár 2007; RAPID); we were able to report Grade 1
fat necrosis, as this had the same definition in all three scales.
Assessment of risk of bias in included studies
BH and ML assessed trials to check that they met the inclusion
criteria and independently assessed methodological quality. BH
undertook ’Risk of bias’ tables assessments, which were checked
by ML, and reported them in the text and as a figure.
We described the risk of bias for each included trial. BH and ML
judged risk of bias in eight specific domains, and resolved any
differences through discussion. The eight domains were:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessors for objective outcomes;
5. blinding of outcome assessors for subjective outcomes;
6. incomplete outcome data;
7. selective outcome reporting;
8. other sources of bias (i.e. early stopping and differences in
follow-up examinations).
We will perform sensitivity analyses on the basis of trial quality
when additional trials are available.Weplan toperform the analysis
both with and without trials at low risk of bias to assess the effect
of bias on the results when more trials are available to examine.
Measures of treatment effect
We presented results as hazard ratios (HR) for time-to-event data
and odds ratios (OR) with 95% confidence intervals (CI) where
this was not possible (Deeks 2004).
For future updates, if we find results for continuous variables (such
as quality of life), we will summarize them using the mean differ-
ence or the standardized mean difference when different measure-
ment scales are used (Deeks 2004).
Unit of analysis issues
Because the unit of analysis was the individual participant, we did
not anticipate any unit of analysis issues.
Dealing with missing data
If data are missing in future updates, we will contact the original
investigators (by written correspondence).
We will specify what assumptions we make, for example, if we
presume the missing data were missing at random, or that miss-
ing data were assumed to have a particular value such as a poor
outcome. We will, if necessary, perform a sensitivity analysis to
see how sensitive results are to the assumptions we have made. We
will address the potential implications of this in the ’Discussion’
section.
Assessment of heterogeneity
We assessed heterogeneity both visually and statistically using the
Chi2 test of heterogeneity (Altman 1992; Walker 1988), and I2
statistic (Higgins 2002; Higgins 2003). The criterion for identifi-
cation of heterogeneity is a P value less than 0.10 for the Chi2 test
(acknowledging the limitations of this process) and an I2 statistic
greater than 50%. Where we identified significant heterogeneity,
we explored the reasons for it and made a cautious attempt to
explain the heterogeneity.
Assessment of reporting biases
We acknowledge that there are multiple potential sources of re-
porting biases, including, but not limited to, publication bias,
time-lag bias, duplicate publication bias and selective outcome re-
porting. By searchingmultiple sources including trial registries, we
hope to minimize publication bias. We noted the early reporting
for the TARGIT was an example of time-lag bias. We planned to
use funnel plots to evaluate funnel plot asymmetry, but took into
account that visual interpretation is subjective and that statistical
methods to evaluate funnel plot asymmetry are unlikely to be valid
if there are fewer than 10 included trials.
Data synthesis
We applied the intention-to-treat principle in analyzing data from
the trials and determined a weighted mean treatment effect using
the fixed-effect model to combine results (Mantel 1959) with Re-
view Manager 5 software (RevMan 2012).
We used the Mantel-Haenszel methods to calculate pooled results
when there was no significant heterogeneity (Greenland 1985;
Mantel 1959), or if otherwise, the random-effects model of Der
Simonian and Laird (DerSimonian 1986).
We excluded two studies from the analysis (Dodwell 2005; Ribeiro
1993), because they used staging, surgery and RT techniques that
do not reflect current practice (see Characteristics of excluded
studies table).
We graded the quality of the evidence and created a ’Summary of
findings’ table using the following outcomes.
1. LR-FS.
2. Cosmesis.
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3. Mortality (follow-up: 5-year survival).
4. Late toxicity: late subcutaneous breast fibrosis.
5. C-SS.
6. DM-FS.
7. Subsequent mastectomy.
The population included women with early breast cancer and the
intervention was PBI/APBI versus WBRT. We used GRADEpro
and the GRADE approach to evaluate the strength of the evidence
(GRADE Working Group 2004). To calculate the absolute risk
for the control group for time-to-event outcomes, we estimated
the event rate at a specific time point (five years for LR-FS, BC-SS,
DM-FS and OS) from the Kaplan-Meier curves or reported event
rates. We entered these estimated values in GRADEpro, which
automatically calculated the corresponding absolute risks for the
intervention group at five years.
Subgroup analysis and investigation of heterogeneity
In future updates if data are available, we may perform subgroup
analyses to investigate whether the effects of using PBI/APBI or
conventional breast RT differ depending on nodal status, margin
status, receptor status, hormonal manipulation or tumour stage.
If heterogeneity is identified in future updates, we will assess it
both statistically and visually using the Chi2 test of heterogeneity
(Altman 1992; Walker 1988), and I2 statistic (Higgins 2002;
Higgins 2003). If we do identify significant heterogeneity, we will
explore the reasons for it and attempt to explain it.
Sensitivity analysis
We performed a sensitivity analysis by excluding the trials at high
risk of bias for subjective outcomes (ELIOT; Livi 2015; Polgár
2007; Rodriguez). In future updates, if adequate data are available,
we will perform a sensitivity analysis to assess the robustness of
the results by excluding studies at high risk of bias for subjective
outcomes and unpublished trials.
R E S U L T S
Description of studies
See: Characteristics of included studies table.
Results of the search
For this review update, based on our search strategy, we identified
and screened 3630 references from the major medical databases
and identified 46 additional references from other sources. Af-
ter exclusion of duplicates and screening of references (by title
or abstract), we evaluated 46 full-text references and excluded
eight references (see Characteristics of excluded studies table).
Of the remaining 38 references, 17 records related to five new
included studies (ELIOT; GEC-ESTRO; Livi 2015; RAPID;
Rodriguez), six records provided data for two previously included
studies (Polgár 2007; TARGIT), 14 records for four ongoing stud-
ies (IMPORT; IRMA; NSABP-B39/RTOG; SHARE), and one
record for one study awaiting classification (NCT02375048).
Overall, when combining the original and review update, there
were 44 records relating to seven included studies, 14 records relat-
ing to four ongoing studies and one record awaiting classification
(see Figure 1). Two studies that were included in the original re-
view have now been excluded (Dodwell 2005; Ribeiro 1993). This
is because the surgery and techniques used to define volume of
breast treated and the technology used in these two studies do not
reflect current RT practice. In sum, this review update included
seven studies and the qualitative analysis included six studies.
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Figure 1. Study flow diagram.
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Included studies
Design
Seven RCTs enrolled 8955 women (ELIOT; GEC-ESTRO; Livi
2015; Polgár 2007; RAPID; Rodriguez; TARGIT); we studied
7586 women included in these studies. These studies enrolled
women from July 1998 to May 2004 (Polgár 2007), February
2006 to July 2011 (RAPID), November 2000 to December 2007
(ELIOT), March 2000 to June 2011 (TARGIT), March 2005
to June 2013 (Livi 2015), and April 2004 to July 2009 (GEC-
ESTRO); Rodriguez did not state accrual dates.
Sample size
Polgár 2007 enrolled 258 women of a planned sample size of 570
participants, RAPID enrolled 2135 women, Rodriguez enrolled
102 women, ELIOT enrolled 1305 women, TARGIT enrolled
3451 women, Livi 2015 enrolled 520 women and GEC-ESTRO
enrolled 1184 women.
Setting
Four studies were single institution trials from tertiary institu-
tions: one in Hungary (Polgár 2007), two in Italy (ELIOT; Livi
2015), and one in Spain (Rodriguez). GEC-ESTRO, TARGIT,
and RAPID were multicentred, international studies.
Participants
Polgár 2007 includedwomenwith invasive breast cancer afterwide
local excision of tumour and negative pathological margins (unifo-
cal tumours, tumour size less than 20 mm, clinically or patholog-
ically N0, or single microscopic nodal metastasis (greater than 0.2
mm and less than 2.0 mm), that is, pT1N0-1miM0, Grade I or
II; T1N0-N1miM0, Grade I or II. RAPID enrolled women with
either invasive ductal carcinoma or ductal carcinoma in situ with
tumours 3.3 cm or greater, with negative margins and no involved
axillary nodes. Rodriguez included women with pT1-2pN0M0
invasive ductal carcinoma, with tumour size 3 cm or less, with neg-
ative margins and Grade I or II histology. ELIOT enrolled women
aged 48 to 75 years with early breast cancer, maximum tumour
diameter 2.5 cm, “suitable for breast conservation”. TARGIT en-
rolled women aged 45 years or over, with T1 and small T2N0-
1M0 invasive breast cancer, suitable for breast-conserving surgery,
available for 10 years’ follow-up. Livi 2015 included women aged
over 40 years who had wide local excision or quadrantectomy for
invasive breast cancer, negative margins and tumour size 2.5 cm or
less. GEC-ESTRO included women aged 40 years or more, small
T1-2N0-miM0 (less than 3 cm) with negative margins and no
lympho-vascular invasion (LVI) and excluded women with multi-
focal tumours. GEC-ESTRO included Tis. See Characteristics of
included studies table.
Interventions
Experimental arm
PBI using either:
1. brachytherapy:
i) high-dose-rate (HDR) brachytherapy: seven × 5.2 Gy
HDR multi-catheter brachytherapy for 88/128 women (Polgár
2007); 30.3 to 32.0 Gy/seven or eight fractions (GEC-ESTRO);
ii) pulsed-dose-rate (PDR) brachytherapy: 50 Gy at 0.6
to 0.8 Gy/hour in GEC-ESTRO or
2. EBRT to partial breast. PBI delivered via EBRT was
delivered:
i) via conventionally fractionated (2 Gy per fraction) in
50 Gy/25 fraction electron beam RT delivered using a linear
accelerator to the partial breast for 40/128 women (Polgár 2007);
ii) at greater than 2 Gy per fraction delivered using a
linear accelerator. RAPID used 3D-CRT in 38.5 Gy/10 fractions
over five to eight days (with a minimum six hour gap between
fractions given on the same day) and Rodriguez used 37.5 Gy/10
fractions twice daily over five days. Livi 2015 delivered 30 Gy in
five fractions using intensity-modulated radiotherapy (IMRT);
iii) using electrons: intraoperative electron therapy to
deliver 21 Gy in one fraction at the 90% isodose delivered at the
time of surgery after tumour excision using 6 to 9 MeV (ELIOT);
iv) using kilovoltage EBRT: TARGIT used a single
fraction of RT given intraoperatively (using Intrabeam); 50 kV
20 Gy/one fraction at 2 mm beyond surface of 1.5 to 5.0 cm
spherical applicator placed in excision cavity.
Control arm
WBRT using conventional fractionation:
1. ELIOT and Polgár 2007 used 50 Gy/25 fractions WBRT;
2. RAPID permitted two doses for WBRT: 50 Gy/25 fractions
or 42.5 Gy/16 fractions;
3. Rodriguez gave 48 Gy in 24 fractions;
4. TARGIT gave “Standard post-operative RT (40 to 56 Gy ±
10 to 16 Gy boost)”;
5. Livi 2015 used 50 Gy/25 fractions plus 10 Gy boost;
6. GEC-ESTRO used 50 to 50.4 Gy in 1.8 to 2.0 Gy/
fraction using 4 to 10 MV beams plus 10 Gy/5 fraction boost.
14Partial breast irradiation for early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Co-interventions
Chemotherapy and hormonal manipulation: in Livi 2015, Polgár
2007, GEC-ESTRO, RAPID, and TARGIT, women received ad-
juvant systemic therapy according to institutional protocol, and
Rodriguez treated oestrogen receptor positive women with hor-
monal manipulation. Systemic therapy in ELIOT was “adminis-
tered according to the European Institute of Oncology policy” at
the time (see Characteristics of included studies table for further
details). In total, 6372/6820 (93%) women received hormonal
manipulation and 977/6820 (14.3%) of the women received che-
motherapy.
ELIOT treated any women with four or more involved nodes with
regional nodal RT. No women in any of the other included studies
received regional nodal RT.
Outcomes
Primary outcomes
Local recurrence-free survival
Six trials reported local recurrence in the ipsilateral breast as a
discrete outcome (GEC-ESTRO; Rodriguez; ELIOT; Livi 2015;
Polgár 2007; TARGIT).
Cosmesis
Six trials reported cosmesis (cosmetic outcome). Polgár 2007,
Livi 2015, and Rodriguez reported a global cosmetic result
(used the Harvard Cosmetic score (see Table 1)) and RAPID
used the EORTC Cosmetic rating System for Breast Cancer
(Aaronson 1998); both were four-point scales. GEC-ESTRO eval-
uated cosmesis using digital photos, with both participant-re-
ported outcomes and physician-reported outcomes using a four-
point scale (Wazer 1992; see Table 2). Rodriguez and RAPID re-
ported participant-reported cosmetic outcomes. RAPID blinded
assessment of cosmetic outcome. TARGIT assessed cosmetic out-
come at a single centre in a sub-study that included 105 women.
A software program, blinded to treatment arm, assessed digital
photos at a median 23 months using a four-point scale.
Secondary outcomes
Overall survival
Six trials reported OS (GEC-ESTRO; Rodriguez; ELIOT; Livi
2015; TARGIT; Polgár 2007).
Toxicity
Four trials reported acute skin toxicity. Rodriguez, Livi 2015, and
TARGIT used the Radiation Therapy Oncology Group Common
Toxicity Criteria (RTOG CTC) (Cox 1995; Table 3) and ELIOT
used a five-point scale (which was not referenced).
Five trials reported late toxicity (telangiectasia (small blood vessels
visible on the treated skin), breast pain, fat necrosis and subcu-
taneous fibrosis). Polgár 2007 reported fat necrosis at four years
according to a five-point institutional scale (Table 4); RAPID re-
ported late RT toxicity (telangiectasia, induration (subcutaneous
fibrosis), breast pain and fat necrosis) using the National Cancer
Institute Common Toxicity Criteria (NCI CTC 3.0; NCI; three-
point scales; Table 5). GEC-ESTRO reported late toxicity (breast
pain, late subcutaneous toxicity and lateRT skin toxicity) using the
RTOG CTC (Cox 1995). ELIOT reported fat necrosis and radi-
ological radiation pneumonitis using late effects of normal tissue -
subjective objective management analytic criteria (LENT-SOMA;
Pavy 1995). Livi 2015 scored late RT toxicity using RTOG CTC
(Cox 1995). TARGIT reported “complications arising six months
after randomisation” and reportedRTOGCTC (Cox 1995)Grade
III or IV RT-related skin complications, haematomas/seromas re-
quiring greater than three aspirations or surgery, wound infections
requiring intravenous antibiotics or surgery and skin breakdown/
delayed wound healing.
New primary tumours in ipsilateral breast (’elsewhere
primaries’)
Three trials reported new primary tumours in ipsilateral breast
(ELIOT; GEC-ESTRO; Livi 2015).
Cause-specific survival
Five trials reported C-SS (where an independent clinician, blinded
to treatment arm, determined cause of death) (ELIOT; GEC-
ESTRO; Livi 2015; Polgár 2007; TARGIT).
Distant metastasis-free survival
Five trials reported DM-FS (ELIOT; GEC-ESTRO; Livi 2015;
Polgár 2007; Rodriguez).
Relapse-free survival
One trial reported R-FS (Polgár 2007).
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Loco-regional recurrence-free survival
Three trials reported L-RR-FS (ELIOT; GEC-ESTRO;
TARGIT).
Subsequent mastectomy
Three trials reported subsequent mastectomy (GEC-ESTRO;
Polgár 2007; TARGIT).
Compliance
Three trials reported compliance (GEC-ESTRO; Polgár 2007;
TARGIT).
Costs
We found no trials reporting cost.
Quality of life
Two trials reported quality of life. RAPID used the Breast Can-
cer Questionnaire (a validated modification of the Breast Can-
cer Chemotherapy Quality of Life Questionnaire; Levine 1998)
and GEC-ESTRO used the EORTC QLQ-C30 and QLQ-BR23
(Levine 1998).
Consumer preference
We found no trials reporting consumer preference.
The included RCTs differed in several ways.
1. Population included: see above.
2. Surgery performed: margins were negative for women in
GEC-ESTRO (2 mm or greater); Rodriguez (greater than 3
mm); Polgár 2007 (less than 2 mm: 1/258, 2 mm or greater:
246/258 or had no tumour at ink: 11/258); RAPID
(“microscopically clear”) and TARGIT (1 mm or greater).
ELIOT did not describe margin status. Surgery in Livi 2015
could be either wide local excision or quadrantectomy (margins
5 mm or greater); in TARGIT if margins were close/involved
(invasive disease or in situ disease 1 mm or greater from margin)
re-excision was strongly advised.
3. Target volume definition for the treated PBI/APBI volume
varied between the trials. Polgár 2007 clipped the cavity and the
planning target volume (PTV) comprised the cavity plus a 1 to 2
cm margin isotropically (in all directions three dimensionally)
for those women treated with interstitial therapy. If electrons
were used, 6 to 15 MeV were used to treat the cavity with a 2 cm
margin. In RAPID, the clinical target volume (CTV) was
defined as the tumour bed seen on computer tomography (CT),
including the surgical clips plus a 1 cm margin, with a 1 cm
margin on CTV to derive PTV. In Rodriguez, the involved breast
quadrant was contoured. In ELIOT, the “clinical target volume
was decided according to the site and size of the tumour”. In Livi
2015, a CTV was drawn on a planning CT with a uniform 1 cm
margin around the surgical clips, then a 1 cm margin added to
construct the PTV. The target volume was the tumour cavity for
TARGIT. In GEC-ESTRO, the target volume was defined
individually for each woman, the CTV was the tumour bed plus
a “safety margin” 2 cm or greater, this was planned using CT.
4. Radiation dose prescribed differed greatly between the
trials. The PBI/APBI arm dose was higher than the WBRT dose
for all studies except ELIOT (see Table 6 for dose, fraction size
and dose prescription point, where it was specified).
5. The trials differed in fractionation used for APBI. In Polgár
2007, most women (88/128) received accelerated RT, RAPID
used 3.85 Gy fractions, Rodriguez delivered 3.75 Gy fractions
using daily RT and Livi 2015 used 6 Gy per fraction.
GEC-ESTRO used seven or eight fractions for HDR and 0.6 to
0.8 Gy pulses for PDR. ELIOT used 21 Gy at the 90% isodose
delivered in a single fraction. TARGIT used 20 Gy to the cavity
surface delivered in a single fraction (Table 6).
6. RT technique for PBI/APBI delivery differed. In Polgár
2007, most women (88/128) in the PBI/APBI arm received
interstitial brachytherapy, but 40/128 women received EBRT, as
they were not suitable for brachytherapy (Table 7). RAPID and
Rodriguez used 3D-CRT (using EBRT); Livi 2015 used IMRT
to deliver EBRT; ELIOT delivered intraoperative electron
therapy at the time of surgery after tumour excision using 6 to 9
MeV and TARGIT inserted a spherical applicator into the
operative bed and sutured it in place to treat the tumour cavity
(see Table 7).
7. Quality assurance differed. RAPID included an extensive
quality assurance programme with credentialling, real-time and
post-hoc review of radiation quality. GEC-ESTRO involved
both pre- and post-implant assessment of geometry using CT,
dose prescription and calculations were in accordance with
International Commission of Radiation Units and
Measurements (ICRU) 58 and strict dose volume histogram and
dose maximums were mandated, the post-hoc quality assurance
requirements were clearly detailed in the study protocol. For the
WBRT component of TARGIT, as long as treating centres
conformed to a formal quality management system issued by the
International Standards Organization, no additional quality
assurance was required. For the APBI, quality assurance
performed according to the manufacturer’s instructions was to be
performed and the resulting data to be made available to the
trials centre. Data were submitted either annually or after every
50th participant treated with Intrabeam. Rodriguez, ELIOT,
and Livi 2015 did not mention trial-specific quality assurance to
assess quality of the delivered RT. Polgár 2007 did not mention
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quality assurance for APBI using electrons or WBRT.
8. One study did not accrue the full sample size: Polgár 2007
stopped early because a competing multicentred RCT was
started.
Excluded studies
In the 2015 review update, we excluded eight studies (see
Characteristics of excluded studies table).
Risk of bias in included studies
Allocation
We judged the risk of bias for random sequence generation and
allocation concealment as follows: ELIOT, GEC-ESTRO, Livi
2015, Livi 2015, RAPID, Rodriguez, and TARGIT were at low
risk of bias for sequence generation. Polgár 2007 was randomized,
the method (sealed envelopes) described and allocation was done
by the chief investigator. TARGIT, Livi 2015, and GEC-ESTRO
were at low risk of bias for allocation concealment. ELIOT,
RAPID, Rodriguez, and Polgár 2007 did not clearly report allo-
cation concealment, so were at unclear risk of bias.
Blinding
Objective outcomes
RAPID and Rodriguez did not mention blinding of participants.
It would have been difficult to do so with this intervention, but
the lack of blinding was unlikely to have introduced bias (Polgár
2007). Participants in GEC-ESTRO, Livi 2015, and TARGIT
were not blinded to treatment arm, but we considered this unlikely
to introduce bias.
ELIOT did not blind participants; for objective outcomes, the
clearly pre-specified criteria for endpoints and the pre-specified
follow-up protocol meant we deemed this domain at low risk of
bias.
The trials did not mention blinding of physicians. It would have
been difficult to do so with this intervention, but failure to do
so is less likely to have introduced bias when the mammographic
screening interval was pre-specified as inGEC-ESTRO, Livi 2015,
RAPID, and Rodriguez. Polgár 2007 had a pre-specified follow-up
protocol with pre-determined interval for mammographic evalu-
ation and Polgár 2007 and Rodriguez required biopsy confirma-
tion for any local recurrence; therefore, this domain was at low
risk of bias. This served to make the objective outcomes at low
risk of bias. In TARGIT, physicians were not blinded to treatment
allocation, which is unlikely to have been a source of bias.
ELIOTdidnot blindpersonnel; for objective outcomes, the clearly
pre-specified criteria for endpoints and the pre-specified follow-
up protocol meant we deemed this domain at low risk of bias.
Polgár 2007 did not mention blinding of outcome assessors, but
the pre-determined mammographic follow-up protocol and re-
quirement for biopsy confirmation of local recurrence would have
reduced the risk of bias. TARGIT did not blind outcome asses-
sors, but the pre-specified follow-up protocol minimized the risk
of bias. TARGIT reported that the analyses were done blinded,
which reduced the risk of bias. ELIOT, GEC-ESTRO, Livi 2015,
RAPID, and Rodriguez were at low risk of bias for this outcome.
Subjective outcomes
Blinding of participants for subjective outcomes was not reported,
but it is unlikely to have introduced bias because only two trials
reported participant-reported outcomes (RAPID; Rodriguez).
Polgár 2007 and Livi 2015 did not mention blinding of physi-
cians and this may have introduced bias. In RAPID, the physician
reviewers were blinded to treatment arm; this was not stated for
the trained nurse observers, but we deemed the outcome at low
risk of bias despite this.
As Polgár 2007 did not mention blinding of outcome assessors, it
is unlikely to have been done and is potentially a source of bias
and, therefore, at high risk of bias. The authors of TARGIT did
not report blinding of outcome assessors, so it seems unlikely that
they were. However, the use of a pre-determined data collection
form for toxicity would have reduced the risk of bias, because
data were collected for all women studied. TARGIT performed a
blinded assessment of cosmesis in a sub-set of 105 women. The
outcome assessors in ELIOT and GEC-ESTRO were not blinded
for assessment of subjective outcomes, so we deemed this domain
at high risk of bias. In Rodriguez, although they noted a partici-
pant-reported outcome, more data came from the physicians (not
blinded to treatment arm), so this outcome of cosmesis was at high
risk of bias.
Incomplete outcome data
ELIOT excluded no women, none were lost to follow-up and
there was no attrition reported, thus this study was at low risk of
bias. Polgár 2007 excluded no women and they reported attrition
by arm (without providing reasons), and the risk of bias was low.
GEC-ESTRO reported on all women randomized, and they re-
ported post-randomization exclusions by arm, with reasons, so we
deemed this at low risk of bias. RAPID and Rodriguez were both
interim reports of ongoing studies, so they were at unclear risk of
bias for this domain. Livi 2015 reported no exclusion or attrition,
so we deemed this at low risk of bias. TARGIT was at low risk of
bias for this domain.
17Partial breast irradiation for early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Selective reporting
For ELIOT, Livi 2015, and Polgár 2007, the trial protocols were
not available for review and we judged them at unclear risk of bias.
TARGIT did not report on all the outcomes pre-specified in the
protocol, but it is likely that these outcomes will form the basis of
future publications so we judged this at low risk of bias. RAPID
and Rodriguez were interim reports; therefore, we deemed them
at unclear risk of bias. GEC-ESTRO did not report on all their
planned outcomes, but stated they will be the subject of a future
paper, so we deemed this domain at low risk of bias.
Other potential sources of bias
Regarding other potential sources of bias: Polgár 2007 had low
risk of bias. Polgár 2007 stopped the trial early because a com-
peting trial started recruiting (GEC-ESTRO). TARGIT had short
median follow-up, which put it at high risk of bias (see Figure 2).
RAPID and Rodriguez were interim reports; therefore, we deemed
them at unclear risk of bias. We identified no other sources of bias
GEC-ESTRO, Livi 2015, or ELIOT, so deemed them at low risk
of bias (see Figure 2).
18Partial breast irradiation for early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison Partial
breast irradiation (PBI)/accelerated partial breast irradiation
(APBI) for early breast cancer
Primary outcomes
Local recurrence-free survival in the ipsilateral breast
There were 89 local recurrences in the 6820 women studied in six
studies.
LR-FS appeared worse with PBI/APBI (HR 1.62, 95%CI 1.11 to
2.35; six studies, 6820 participants; Analysis 1.1; Figure 3). There
was evidence of heterogeneity on visual inspection and statistical
testing (P value = 0.008, I2 = 71%).
Figure 3. Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation
(APBI) versus whole breast radiotherapy (WBRT), outcome: 1.1 Local recurrence-free survival.
We performed sensitivity analysis based on excluding studies
deemed at high risk of bias (for the domains of objective outcomes
and other bias; TARGIT).We found PBI/APBI versusWBRTwas
associated with worse LR-FS (HR 1.48, 95% CI 0.95 to 2.29).
There appeared to be some evidence of heterogeneity both on vi-
sual inspection and statistical testing (P value = 0.07, I2 = 68.6%).
Cosmesis
Cosmetic outcome appears worse with PBI/APBI when:
1. participant-reported (OR 1.74, 95% CI 1.06 to 2.87; P
value = 0.03, not tested for heterogeneity). We identified 89
events in 328 participants from one study (RAPID);
2. assessed by trained nurse observers (OR 3.14, 95% CI 1.81
to 5.45; P value < 0.0001). We did not test for heterogeneity, as
we studied 78 events in 335 participants deriving from one study
(RAPID);
3. physician-reported (OR 1.51, 95% CI 1.17 to 1.95; P value
= 0.002). There was considerable heterogeneity (I2 = 88%; P
value = 0.00004; Analysis 1.2). We studied 315 events in 1720
participants in five studies.
We performed sensitivity analysis by excluding studies at high risk
of bias for blinding of outcome assessors for subjective outcomes (
ELIOT; Livi 2015; Polgár 2007;Rodriguez) for physician reported
cosmesis. We found cosmesis was worse with PBI/APBI versus
WBRT (OR 2.32, 95% CI 1.69 to 3.18; P value = 0.00001).
Testing for heterogeneity revealed the presence of considerable
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heterogeneity (I2 = 84%; P value = 0.01).
Secondary outcomes
Overall survival
We found no difference in OS with PBI/APBI versus WBRT with
data from 268 deaths in five studies with 6718 participants (HR
0.90, 95%CI 0.74 to 1.09; P value = 0.27; Analysis 1.3; Figure 4).
There was no heterogeneity on either visual inspection or statistical
testing (I2 = 40%; P value = 0.15).
Figure 4. Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation
(APBI) versus whole breast radiotherapy (WBRT), outcome: 1.3 Overall survival.
Toxicity
PBI/APBI reduced acute skin toxicity compared withWBRT (OR
0.04, 95% CI 0.02 to 0.09; P value < 0.00001; Analysis 1.4). We
studied 150 events in 608 participants in two studies. We found
little evidence of heterogeneity (I2 = 27%; P value = 0.24).
There was no different in haematomas needing surgical aspiration
between APBI and WBRT (P value = 0.338; figure from text;
TARGIT).
Seromas needing greater than three aspirationsweremore frequent
with APBI compared with WBRT (P value = 0.012; figure from
text; TARGIT).
There was no difference in infection requiring intravenous antibi-
otics or surgical intervention between APBI and WBRT (P value
= 0.292; figure from text; TARGIT).
There was no difference in skin breakdown or delayed healing
between APBI and WBRT (P value = 0.155; figure from text;
TARGIT).
Regarding late toxicity:
1. there was no difference in late skin toxicity with PBI/APBI
versus WBRT (OR 0.21, 95% CI 0.01 to 4.39; P value = 0.31;
data from two events in 608 participants in two studies; Analysis
1.5). There was no difference in late RT skin toxicity between
PBI and WBRT in GEC-ESTRO (P value = 0.08; figure from
text);
2. telangiectasia appeared worse with PBI/APBI compared
with PBI (OR 26.56, 95% CI 3.59 to 196.51; P value = 0.001;
data from one study with 28 events in 766 evaluable women;
RAPID);
3. PBI/APBI increased radiological fat necrosis compared with
WBRT (OR 1.58, 95% CI 1.02 to 2.43; P value = 0.04; three
studies with 100 events in 1319 participants). We found little
evidence of heterogeneity (I2 = 49%; P value = 0.14; Analysis
1.6);
4. PBI/APBI increased subcutaneous fibrosis compared with
WBRT (OR 6.58, 95% CI 3.08 to 14.06; P value < 0.00001;
data from one study with 59 events in 766 women). There was
no difference in late subcutaneous toxicity between PBI and
WBRT in GEC-ESTRO (P value = 0.53; figures from text);
5. there was no difference in breast pain with PBI/APBI versus
WBRT (OR 2.17, 95% CI 0.56 to 8.44; P value = 0.27; 10
events in one study with 766 evaluable women); ELIOT
reported no difference in breast pain (data not shown). Breast
pain was reduced with PBI compared with WBRT in
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GEC-ESTRO (P value = 0.04; figures from text).
New primary tumours in ipsilateral breast ’elsewhere
primaries’
New primaries in the treated breast appeared more frequent with
PBI/APBI compared with WBRT (OR 3.97, 95% CI 1.51 to
10.41; Analysis 1.7). There were 24 events in 3009 participants
in three studies. There was evidence of heterogeneity (I2 = 74%;
P value = 0.02).
Cause-specific survival
We found no clear evidence that C-SS differed with PBI/APBI
versus WBRT (HR 1.08, 95% CI 0.73 to 1.58, 107 breast cancer
deaths in 6718 participants in five studies; Analysis 1.8; Figure 5).
We found no evidence of heterogeneity on either visual inspection
or statistical testing (I2 = 0%; P value = 0.81; Analysis 1.8).
Figure 5. Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation
(APBI) versus whole breast radiotherapy (WBRT), outcome: 1.8 Cause-specific survival.
Distant metastasis-free survival
We found no clear evidence that DM-FS differed with PBI/APBI
versusWBRT (HR 0.94, 95%CI 0.65 to 1.37, 110 events in 3267
participants in four studies; Analysis 1.9; Figure 6). We found no
heterogeneity with either visual inspection or statistical testing (I
2 = 0%; P value = 1.0).
Figure 6. Forest plot of comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation
(APBI) versus whole breast radiotherapy (WBRT), outcome: 1.9 Distant metastasis-free survival.
Relapse-free survival
We found no clear evidence that R-FS differed with PBI/APBI
versus WBRT (HR 1.36, 95% CI 0.88 to 2.09; P value = 0.16; 87
relapses in 3811 participants in three studies; Analysis 1.10). We
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found little evidence of heterogeneity (I2 = 46%; P value = 0.17).
R-FS did not differ in GEC-ESTRO (P value = 0.79; figure from
text).
Loco-regional recurrence-free survival
We found that L-RR-FS was worse with PBI/APBI versus WBRT
(HR 1.80, 95% CI 1.00 to 3.25; Analysis 1.11). We studied 48
events in 3553 participants in two studies.
Subsequent mastectomy
Subsequentmastectomy rate did not appear to differ between PBI/
APBI andWBRT (OR1.20, 95%CI 0.77 to 1.87; Analysis 1.12).
There were 79 events in 4817 participants in three studies. There
was no evidence of heterogeneity (I2 = 0%; P value = 0.45).
Compliance
Greater than 90% of the women randomized to PBI/APBI re-
ceived treatment in all of the included studies. For those women
randomized to receive WBRT, greater than 90% of the women
received the planned RT in all of the included studies.
Costs
There were no data on costs.
Quality of life
There were no data on quality of life, although it was assessed in
RAPID.
Consumer preference
There were no data on consumer preference.
D I S C U S S I O N
Summary of main results
LR-FS appeared worse with PBI/APBI compared with WBRT
(Analysis 1.1). Cosmetic outcome appeared worse with PBI/APBI
comparedwithWBRTwhen participant-reported (OR1.74, 95%
CI1.06 to 2.87; P value =0.03), assessed by trainednurse observers
(OR 3.14, 95% CI 1.81 to 5.45; P value = 0.00001) or physician-
reported (OR 1.51, 95% CI 1.17 to 1.95; P value = 0.002) (
Analysis 1.2).
We found no evidence of a difference in OS when PBI/APBI was
used compared with WBRT (HR 0.90, 95% CI 0.74 to 1.09; P
value = 0.27; Analysis 1.3).
We found PBI/APBI versus WBRT was associated with decreased
acute skin toxicity (OR 0.04, 95% CI 0.02 to 0.09; P value <
0.00001; Analysis 1.4). Late skin toxicity did not differ with PBI/
APBI versusWBRT, neither did breast pain, butwe found itwas as-
sociated with more telangiectasia, radiologically evident fat necro-
sis and more subcutaneous fibrosis. We found PBI/APBI versus
WBRT was associated with more ’elsewhere primaries’ (OR 3.97,
95% CI 1.51 to 10.41; Analysis 1.7).
We found no clear evidence of a difference in C-SS (Analysis
1.8), DM-FS (Analysis 1.9) or R-FS (Analysis 1.10) with PBI/
APBI compared withWBRT but we could not exclude potentially
important differences between the treatment groups. We found
no difference with PBI/APBI versus WBRT for L-RR-FS (HR
1.80, 95% CI 1.00 to 3.25; P value = 0.05; Analysis 1.11). The
mastectomy rate did not appear affectedwith PBI/APBI compared
withWBRT(Analysis 1.12).Compliancewith allocated treatment
was high at greater than 90% for all women studied. We found
no data for the effects of PBI/APBI and WBRT on costs, quality
of life and consumer preference.
Based on these findings, PBI/APBI appeared to be associated with
worse LR-FS in comparison to WBRT. Local relapse was rare in
the carefully selected participant population in this review. Local
relapse was increased by 5 per 1000 women (range 1/1000 to 11/
1000) with PBI/APBI. The use of PBI/APBI was associated with
decreased acute toxicity. There was no strong evidence that PBI/
APBI was associated with increased breast pain or late skin toxicity.
We found that PBI/APBI caused increased telangiectasia, radio-
logically evident fat necrosis (Table 4) and subcutaneous fibrosis
(see Results, Description of studies, included studies for defini-
tions).
Overall completeness and applicability of
evidence
There were limitations in completeness and applicability of evi-
dence due to clinical heterogeneity between the trials, duration of
follow-up and little or no useful information available for some
outcome measures.
Clinical heterogeneity between the trials
There was evident clinical heterogeneity in both the study partic-
ipants and the interventions.
The PBI/APBI delivered was heterogeneous in dose, technique,
fractionation and target delineation.
1. The RT doses varied between the trials. In all studies, the
EQD2 delivered in the APBI arm was higher than the WBRT
dose (with the exception of ELIOT; see Table 6). Despite the
dose escalation in the APBI arm, we found that LR-FS was worse
with APBI, which suggests there may be technical issues with RT
delivery (e.g. target volume definition or target coverage).
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2. The RT techniques used to deliver PBI/APBI varied (see
Table 7).
3. The trials differed in fractionation used; all the studies used
greater than 2 Gy per fraction in the experimental arm, with the
exception of Polgár 2007, where some of the women in the PBI/
APBI arm received 2 Gy per fraction (see Table 6).
4. The techniques used to define the target volume in
GEC-ESTRO, Livi 2015, Polgár 2007, RAPID, and TARGIT
were consistent with current practice, but ELIOT provided
inadequate details for the technique used in to be certain of this.
Avoiding geographic miss is imperative in RT. Delivery of RT is
a technical exercise. Peters 2010 demonstrated the extremely im-
portant role that quality assurance plays in the delivery of high-
quality RT. Poor-quality RT (a non-compliant plan) for locally
advanced head and neck cancer was associated with a 20% detri-
ment in survival and a 29% detriment to loco-regional control
(Peters 2010). Three studies did not mention quality assurance
(ELIOT; Livi 2015; Rodriguez). Although Polgár 2007 assessed
implant quality, less than 20% of the implants had post-implant
CT to document PTV coverage and quality assurance for APBI
using electrons or WBRT was not mentioned (see Characteristics
of included studies table). RAPID included an extensive quality
assurance programme with credentialling, real-time and post-hoc
review of radiation quality. GEC-ESTRO had rigorous pre- and
post-implant quality assurance procedures.
The lack of precision in target definition, the variety of methods
used to deliver PBI/APBI (even within the experimental arm of
the trials; see Table 7) and the omission of robust quality assur-
ance mean that the RT delivered in some of the trials was not
reproducible. We cannot be certain of the dose delivered and the
volume of breast treated.
We found there was heterogeneity for the outcome of cosmesis
(physician-reported). There were some possible sources of clinical
heterogeneity that may have contributed to this: in Polgár 2007,
40/128 (30%) women in the PBI/APBI arm received 50 Gy in 25
fractions to the tumour bed using EBRT; these women who had
conventionally fractionated RT at the same dose as the WBRT
arm were likely to have very similar cosmetic outcome. Livi 2015
delivered PBI/APBI using IMRT, with careful dose constraints
applied: we know that IMRT is associated with improvement in
cosmetic outcome in the setting ofWBRT (Donovan 2007; Pignol
2008).
Modern breast-conserving therapy with postoperative WBRT
achieves local control rates of 3.3% to 3.4% at five years and 5.2%
to 6.7% at 10 years (Haviland 2013). With careful participant
selection (aged 65 years or greater, T1-2 tumours, not greater than
3 cm, margin negative, oestrogen receptor positive and all receiv-
ing tamoxifen), surgery alone can achieve local recurrence rates of
4.1% at five years (Kunkler 2015). The risk of local recurrence
continues with longer follow-up, in modern series where women
with good prognosis were treated with surgery alone, the 10-year
risk of loco-regional or distant recurrence was 19.9% (reduced to
6.3% with RT; Blamey 2013; Fisher 2002; Fyles 2004; Hughes
2004; Potter 2007; Prescott 2007; Winzer 2010). Even if PBI/
APBI is poorly targeted, in a low-risk population being treated
with systemic therapy, low local recurrence rates can be expected.
The paradigm for PBI/APBI relies on the basis that WBRT does
not reduce the number of ’elsewhere primaries’ within the treated
breast, but we found that PBI/APBI appeared to be associated
with an increase in ’elsewhere primaries’ (OR 3.97, 95% CI 1.51
to 10.41; Analysis 1.7).
Duration of follow-up
The length of follow-up in five of the included trials was adequate
to detect local recurrences (10 years (Polgár 2007), 69 months
(ELIOT), 65 months (Livi 2015), 60 months (Rodriguez), 79.2
months (GEC-ESTRO)). The median follow-up for TARGIT, of
29 months, made it inadequate for the outcome of local control.
Local recurrences do continue to increase over time (at about 1%
per year), as can be seen in the START data: 3.3% to 3.4% at
five years and 5.2% to 6.7% at 10 years (Haviland 2013). Any
effect on breast C-SS related to local control requires much longer
follow-up (EBCTCG 2011). None of the included trials had long
enough follow-up to report OS results.
We know that RT reduces the risk of any first recurrence, and
although the proportional reduction is most evident in the first
year post-treatment, it is still present in years five to nine (RR 0.59,
95% CI 0.5 to 0.7; EBCTCG 2011). Even in modern studies that
included low-risk women treated with lumpectomy (enrolled after
1989), the 10-year risk of loco-regional and distant recurrence was
19.9% (reduced to 6.3% with RT; Blamey 2013; Fisher 2002;
Fyles 2004; Hughes 2004; Potter 2007; Prescott 2007; Winzer
2010). Even women at low risk of recurrence (if they are at risk
for another 30 years) are likely to have increases in recurrence with
longer follow-up. The use of PBI/APBI may mean they are at risk
of ’elsewhere primaries’ for this time period.
Little or no useful information available for some
outcome measures
The authors of TARGIT (completed, but with short follow-up)
indicated that cosmesis, participant satisfaction, health economics
and participant preference will be the subject of a sub-protocol
and information with respect to these outcomes will be available
in the future. The five ongoing trials that we found are likely to
address these outcomes (IMPORT; IRMA; NSABP-B39/RTOG;
SHARE; see Characteristics of ongoing studies table).
Quality of the evidence
The available evidence does allow for the drawing of robust con-
clusions in respect of the objective of the review: to determine
whether PBI/APBI is equivalent to or better than conventional
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or hypo-fractionated WBRT after breast-conserving therapy for
early-stage breast cancer. We found seven studies with 8895 par-
ticipants.
LR-FS: we downgraded for risk of bias because 3451/6820 (38%)
women contributing to this outcome came from a study deemed
at high risk of bias because of short follow-up. We did not down-
grade for indirectness because the included studies used contem-
porary RT techniques. With respect to inconsistency (I2 = 71%; P
value = 0.008), there was considerable clinical heterogeneity with
respect to RT dose, technique and use of quality assurance proce-
dures. However, the RT techniques employed all delivered a dose
that was the same or higher in the PBI/APBI arm than theWBRT
arm, which should mean the LR-FS is better or the same (see Table
6). We downgraded for imprecision; there were fewer than 300
events, and although the optimum information size (OIS) had
been met, the CIs did not exclude either clinically unimportant
harms or clinically important harms. We did not downgrade for
publication bias, given the systematic literature search we had per-
formed. The overall GRADE (GRADE Working Group 2004)
quality of evidence for this outcomes was low.
Cosmesis: we did not downgrade for risk of bias because less than
30% of events came from studies at high risk of bias for lack of
blinding of outcome assessors, which is particularly important for
a subjective outcome such as cosmesis. We did not downgrade for
indirectness, but did so for inconsistency (I2 = 88%; P value <
0.00001) even though all assessments used the same four-point
scale. We did downgrade for imprecision (there were greater than
300 events (315 events)) and the CIs did not exclude the pos-
sibility of clinically unimportant harms. We did not downgrade
for publication bias given the systematic literature search we had
performed. The overall GRADE (GRADEWorking Group 2004)
quality of evidence for this outcomes was low.
OS: we did not downgrade for risk of bias, indirectness, inconsis-
tency (I2 = 40%; P value = 0.15) or imprecision (the CIs crossed
one, but excluded clinically significant harms or benefits). We
did not downgrade for publication bias (based on examination of
a Funnel plot). The overall GRADE (GRADE Working Group
2004) quality of evidence for this outcome was high.
Late RT toxicity (subcutaneous fibrosis): we did not downgrade
for risk of bias, indirectness or inconsistency (heterogeneity testing
was not appropriate as only one study contributed data for this
outcome). We downgraded for imprecision, as there were fewer
than 300 events and the OIS was not met (the studies in PBI/
APBI were powered for other endpoints than this one) and CIs did
not exclude clinically important harms.We did not downgrade for
publication bias. The overall GRADE (GRADE Working Group
2004) quality of evidence for this outcomes was moderate.
C-SS: we did not downgrade for risk of bias, indirectness or incon-
sistency (I2 = 0%; P value = 0.81). We did downgrade for impre-
cision, given there were fewer than 300 events (99 events) and the
CIs did not include the possibility of clinically significant benefits
or harms from PBI/APBI. We did not downgrade for publication
bias for this outcome. The overall GRADE (GRADE Working
Group 2004) quality of evidence for this outcomes was moderate.
DM-FS: we did not downgrade for risk of bias, indirectness or in-
consistency (I2 = 0%; P value = 1.0).We did downgrade for impre-
cision as there were fewer than 300 events (100 events) and the CIs
did not exclude clinical meaningful benefits or harms. We did not
downgrade for publication bias. The overall GRADE (GRADE
Working Group 2004) quality of evidence for this outcomes was
moderate.
Subsequent mastectomy: we downgraded for risk of bias, because
one of the studies contributing data had follow-up too short for
assessment of this outcome.Wedidnot downgrade for indirectness
or inconsistency (I2 = 0%; P value = 0.45). We did downgrade for
imprecision as there were fewer than 300 events (78 events) and
the CIs did not exclude clinically meaningful benefits or harms.
The overall GRADE (GRADE Working Group 2004) quality of
evidence for this outcomes was low.
Refer to the Summary of findings for the main comparison.
Potential biases in the review process
We consider that we have identified all the relevant completed
RCTs. For reporting of adverse effects, the precision was low be-
cause the OIS was not met. This may improve in future updates,
as more information with respect to these outcomes is reported.
Agreements and disagreements with other
studies or reviews
We found five systematic reviews examining PBI/APBI compared
with WBRT.
We found one meta-analysis (Valachis 2010), which included one
study (Polgár 2007) in commonwith our systematic review and re-
cruited 1140 women (Dodwell 2005; Polgár 2007; Ribeiro 1993).
They found no difference for mortality (OR 0.91, 95% CI 0.67
to 1.23; P value = 0.55) and distant metastasis (OR 0.74, 95%
CI 0.51 to 1.08; P value = 0.12) for the comparison of PBI/APBI
versus WBRT. PBI/APBI was associated with increased local re-
currence (OR 2.15, 95% CI 1.40 to 3.31; P value = 0.001) and
axillary recurrence (OR 3.43, 95% CI 2.06 to 5.71; P value <
0.0001) when compared with WBRT. They concluded that PBI
does not seem to jeopardize survival and may be used as an al-
ternative to WBRT (Valachis 2010). The authors pooled the data
from the trials (see Data synthesis section).
We found one systematic review with a search date in 2010
(BlueCross BlueShield). They included two RCTs (Polgár 2007;
Ribeiro 1993 (which we excluded)) and seven non-RCTs. They
concluded that “the body of evidence on interstitial PBI/APBI
compared to conventional whole-breast irradiation is weak, and
it is extremely weak (i.e. no comparative studies) for balloon
brachytherapy, intraoperative PBI/APBI, and external-beam PBI/
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APBI. The data on PBI/APBI compared to whole-breast irradi-
ation are insufficient to draw any conclusions about the relative
effectiveness of these modalities. Furthermore, it is becoming in-
creasingly clear that each type of PBI/APBI should be judged on its
ownmerits, and studies comparing different PBI/APBI techniques
to each other as well as to whole-breast irradiation are needed”
(BlueCross BlueShield).
We found one review that used a systematic search (search date
February 2014) (Marta 2015). Our review differed in that we
included updated data for TARGIT and they included Dodwell
2005 and Ribeiro 1993 (which we excluded). They reported de-
creased local control with APBI versus WBRT (HR 4.54, 95%
CI 1.78 to 11.61; P value = 0.002). They concluded that APBI
was associated with an increase in local recurrence, but found no
difference in other outcomes.
Kong 2014 did a systematic search (search date June 2012). They
included 10 studies, and included two retrospective cohorts, two
matched pair analyses and three prospective cohort studies. They
found that PBI/APBI was associated with increased local recur-
rence (OR 1.54, 95% CI 1.15 to 2.06; P value = 0.004). They
found no difference for the comparison of PBI/APBI for the out-
comes of distant metastases, OS and disease-free survival.
One review by Ye 2013 studied 919 women in four studies; their
search was not systematic (search date June 2013). They included
a matched pair analysis, and the fourth study was not referenced.
They reported no difference in local control, but appeared to have
double counted the data for Polgár 2007 at two time points. They
concluded that other outcomes did not differ, although they re-
ported more women who were treated with APBI had good/ex-
cellent cosmesis.
The review inClinical Evidence (search dateApril 2009) compared
intraoperative RT versus standard postoperative RT in women
receiving breast-conserving surgery, and found no fully published
RCTs (see comment, ASERNIP-S 2002). The review concluded,
“Studies are currently attempting to address the question as to
whether partial breast irradiation may be sufficient treatment for
some sub-groups of breast cancer. Until those studies are complete
and the follow-up data mature, it is not possible to recommend
partial breast irradiation as an appropriate treatment for breast
cancer outside of a properly conducted trial” (Clinical Evidence).
Several guidelines have been published on PBI/APBI. The Amer-
ican Society of Therapeutic Radiology and Oncology (ASTRO)
consensus evolved because it was clear that many women are
treated in the US with PBI/APBI outside clinical trials (over
32,000 women have had treatment using MammoSite®; Cytec).
They indicated a patient population “suitable” for PBI/APBI out-
side the context of a clinical trial: women aged 60 years and over,
with pT1N0(i-, i+)M0, margins greater than 2 mm, unifocal dis-
ease, oestrogen receptor positive, who have had no neoadjuvant
therapy. They also described women deemed unsuitable for PBI/
APBI. They state that, “patients who choose treatment with PBI/
APBI should be informed that whole-breast irradiation (WBI) is
an established treatment with a much longer track record that
has documented long-term effectiveness and safety” (Smith 2009).
This statement provides guidance in selecting participants who
may be appropriate for PBI/APBI outside the context of a clinical
trial, but the Task Force strongly endorsed enrolment of all eligi-
ble participants considering PBI/APBI onto NSABP-B39/RTOG
and encouraged enrolment of other participants considering PBI/
APBI, particularly those not in the “suitable” group, into prospec-
tive clinical studies to address many of the unanswered questions
in PBI/APBI (Smith 2009). NCCN states, “patients are encour-
aged to enter clinical trials, and endorses the ASTRO guidelines”.
In the absence of an available trial, the American College of Ra-
diology (ACR) Appropriateness Criteria® panel recommends fol-
lowing the consensus guidelines of the ASTRO (Bellon 2011).
The GEC-ESTRO Breast Cancer Working Group recommends
three categories guiding patient selection for PBI/APBI:
1. a low-risk group for whom PBI/APBI outside the context of
a clinical trial is an acceptable treatment option; including
participants aged at least 50 years with unicentric, unifocal, pT1-
2 (less than 30 mm) pN0, non-lobular invasive breast cancer
without the presence of an extensive intraductal component
(EIC) and LVI and with negative surgical margins of at least 2
mm;
2. a high-risk group, for whom PBI/APBI is considered
contraindicated; including participants aged 40 years or less;
having positive margins, with or without any of the following
pathological features (multicentric or large (greater than 30 mm)
tumours, EIC positive or LVI positive tumours, four or more
positive lymph nodes, unknown axillary status (pNx)); and
3. an intermediate-risk group, for whom PBI/APBI is
considered acceptable only in the context of prospective clinical
trials (Polgár 2010).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It appears that local recurrence and ’elsewhere primaries’ (new
primaries in the ipsilateral breast) are increased with accelerated
partial breast irradiation (APBI) or partial breast irradiation (PBI),
that is, APBI does not offer the same cancer control as whole breast
radiotherapy (WBRT) (but the difference is small). We found no
evidence of detriment to other oncological outcomes. It appears
that cosmetic outcomes and some late effects are worse with PBI/
APBI but its use is associated with less acute skin toxicity. The
limitations of the data currently available mean that we cannot
make definitive conclusions about the efficacy and safety or ways
to deliver of PBI/APBI. We await completion of ongoing trials.
Implications for research
The ongoing trials will address relevant clinical outcomes. PBI/
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APBI is a highly technical intervention that is operator dependent
and requires careful quality assurance. Interpretation of these trials
will require consideration of the quality of the RT delivered, with
respect to target definition and treatment verification.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ELIOT
Methods Phase III RCT
Single-centred, tertiary institution
Country: Italy
Median follow-up: 68 months
Participants Women aged 48-75 years with early breast cancer, maximum tumour diameter 2.5 cm,
”suitable for breast conservation“. All women with positive sentinel node biopsy had
axillary dissection
Interventions Experimental arm: intraoperative electron therapy to deliver 21 Gy at the 90% isodose
delivered at the time of surgery after tumour excision using 6-9 MeV
Control arm: postoperative EBRT (50 Gy/25 fractions + 10 Gy/5 fraction boost using
electrons)
Outcomes 1. Ipsilateral breast tumour recurrence that included both local recurrence and new
ipsilateral breast primaries
2. Overall survival
3. Regional nodal failure
4. Distant metastases
5. Late toxicity (measured using LENT-SOMA
Notes Target volume: 4-12 MeV to 90% isodose 10-30 mm around sutured surgical breach
NB: women with ≥ 4 involved nodes were treated with RNI (50 Gy/25 fractions).
Adjuvant therapies were administered according to the European Institute of Oncology
policy at the time
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”At the data centre, allocation was
done by telephone with a computer-gener-
ated list using a randomly permuted block
design, stratified by tumour size (<1.0 cm
vs 1.0-1.4 cm vs ≥1.5 cm)“, page 1270,
paragraph 3
This method represented an adequate ran-
domization method, therefore, we judged
this domain at low risk of bias
Allocation concealment (selection bias) Unclear risk Quote: ”Immediately before the interven-
tion, the surgeon contacted the data cen-
tre by telephone to receive the allocation
group. At the data centre, allocation was
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ELIOT (Continued)
done by telephone“, page 1270, paragraph
3
Because the details of how this was done
were not reported, we judged this domain
at unclear risk of bias
Blinding of participants and personnel
(performance bias) Objective outcomes
Low risk Quote: ”Study coordinators, clinicianswho
verified eligibility criteria after pathological
assessment of the surgical specimen, clini-
cians who followed up patients, investiga-
tors who did the statistical analyses, and the
patients themselves were aware of the as-
signment“, page 1270, paragraph 3
We judged this domain at low risk of bias
Blinding of participants and personnel
(performance bias) Subjective outcomes
Low risk Quote: ”Study coordinators... clinicians
who followeduppatients... and the patients
themselves were aware of the assignment“,
page 1270, paragraph 3
We judged this domain at low risk of bias
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: ”We defined local recurrence as the
reappearance of the carcinoma at the site of
the surgical intervention. We defined sec-
ond ipsilateral breast tumours as any new
carcinoma appearing in other quadrants of
the same breast. IBTR was defined as the
sum of local recurrence plus second ipsilat-
eral tumours. A regional nodal failure in-
cluded any recurrence in the ipsilateral axil-
lary, supraclavicular, or internal mammary
nodal regions. Distant metastases were de-
fined as any recurrence to distant organs.
Overall survival was defined as the time
from diagnosis to last follow-up or time of
death“
Quote: ”Patients were followed up with a
clinical examination every 3months, an ul-
trasound mammary scan every 6 months,
and a mammogram every year; examina-
tions of the lung, liver, and bone weremod-
ulated according to a personalised assess-
ment of risk“
Quote: ”investigators who did the statisti-
cal analyses“, page 1270, paragraph 3
Although the outcome assessors for objec-
tive outcomes were not blinded, the clear
pre-specified definitions of what consti-
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ELIOT (Continued)
tuted outcomes and the pre-specified fol-
low-up protocol reduced the risk of bias for
this domain
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Quote: ”Study coordinators, clinicianswho
verified eligibility criteria after pathological
assessment of the surgical specimen, clini-
cians who followed up patients, investiga-
tors who did the statistical analyses, and the
patients themselves were aware of the as-
signment”, page 1270, paragraph 3
Quote: “Side-effects were scored using the
Late Effect of Normal Tissue- Subjective
Objective Management Analytic criteria”
Because the assessment of subjective out-
comes was not blinded, we judged this do-
main at high risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions were reported and there was
no post-randomization attrition (see Figure
1) so we judged this domain at low risk of
bias
Selective reporting (reporting bias) Unclear risk Outcomes specified in paper:
1. Primary outcome: IBTR (in breast
true recurrences)
2. Secondary outcome: overall survival
Outcomes reported:
1. IBTR
2. True local recurrences
3. New ipsilateral breast cancer
4. Loco-regional recurrence
5. Contralateral breast cancer
6. Distant metastases
7. Non-breast cancer in other sites
8. Overall survival
9. Breast cancer deaths
10. Skin radiation toxicity
11. Pulmonary fibrosis
We did not have access to the study proto-
col, so judged this domain at unclear risk
of bias
Other bias Low risk No other sources of bias identified
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GEC-ESTRO
Methods Phase III RCT
Open-label trial
Country: Germany
Median follow-up: 79.2 months
Participants Women aged > 40 years with Stage 0, I or II breast cancer (including DCIS), no lymph
or vascular invasion, lesions < 3 cm in diameter, pN0/pNmi, DCIS alone, sentinel node
biopsy optional. Clear margin (≥ 2 mm in invasive disease, 5 mm in DCIS), unifocal
or unicentric disease only
Interventions Experimental arm: APBI
Interstitial brachytherapy
HDR 32 Gy/8 fractions or 30.3 Gy/7 fractions
PDR 50 Gy at 0.6-0.8 Gy/fractions given hourly
Control arm: external beam WBRT 50.0-50.4 Gy/1.8-2.0 Gy fractions (5-28) plus 10
Gy/5 fraction boost
Outcomes Primary:
1. Local control
Secondary:
1. Incidence and severity of acute and late adverse effects
2. Differences in cosmetic results
3. Distant metastases disease-free survival
4. Survival rates (overall survival, disease-free survival)
5. Contralateral breast cancer rate
6. Quality of life
Notes Target volume: tumour bed plus 20- to 30-mm radial margin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation was stratified
by study centre, menopausal status, and
tumour type (e.g., invasive carcinoma vs
DCIS), with a block size of ten, according
to an automated dynamic algorithm”, page
3, randomization and masking, paragraph
1
We judged this at low risk of bias
Allocation concealment (selection bias) Low risk Quote: “Patients were randomised cen-
trally at the Department of Medical Infor-
matics, Biometry and Epidemiology, Uni-
versity Erlangen-Nuremberg, Germany, via
an online interface”, page 3, randomization
and masking, paragraph 1
This processwas described as concealed and
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GEC-ESTRO (Continued)
remote, so we judged this at low risk of bias
Blinding of participants and personnel
(performance bias) Objective outcomes
Low risk Quote: “Neither patients nor investigators
were masked to treatment allocation”, page
3, randomization and masking, paragraph
1
Although participants and personnel were
not blinded, it is unlikely to have intro-
duced bias, sowe judged this domain at low
risk of bias
Blinding of participants and personnel
(performance bias) Subjective outcomes
Low risk Quote: “Neither patients nor investigators
were masked to treatment allocation”, page
3, randomization and masking, paragraph
1
Although participants and personnel were
not blinded, it is unlikely to have intro-
duced bias, sowe judged this domain at low
risk of bias
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Follow up mammography was
scheduled at 6, 12, 18 and 24 months after
radiation therapy”, page 3, paragraph 8
Although outcome assessors were not
blinded, we considered the pre-specified
follow-up protocol meant this domain was
at low risk of bias
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Quote: “Clinical examination included
documentation of late side-effects with
Common Terminology Criteria for Ad-
verse Events and with the Radiation Ther-
apy Oncology Group (RTOG)/European
Organisation for Research and Treatment
of Cancer (EORTC) Late Radiation Mor-
bidity Scoring Schema 14”, page 3
Blinding of outcome assessors was not
mentioned, we thought despite the pre-
specified follow-up schema and the use of
a Grading system for documenting late ef-
fects, meant this domain was at high risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “after randomisation, 98 patients..
.administrative error”, page 4, paragraph 1
Post-randomization exclusions are detailed
by arm, with reasons, so we deemed this
outcome at low risk of bias
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GEC-ESTRO (Continued)
Selective reporting (reporting bias) Low risk Quote: “Detailed analyses of early and late
side-effects, quality of life, and cosmetic re-
sults are not presented here”, page 4, para-
graph 1
Although detailed reporting of acute and
late adverse effects and quality of life were
not in this publication, the authors made it
clear there will be further publications, so
we judged this at low risk of bias. We had
access to the study protocol
Other bias Low risk We did not consider there was other bias,
so judged this domain at low risk of bias
Livi 2015
Methods RCT
Single centre
Setting: cancer centre
Country: Italy
Median follow-up: 60 months
Participants Women aged > 40 years, wide local excision or quadrantectomy for invasive breast cancer,
negative margins, tumour size ≤ 25 mm
Interventions PBI/APBI (using IMRT) vs. WBRT (conventional RT)
Outcomes Not specified in report
Notes Study has not completed accrual (target 520 women)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned
to receive eitherWBI or APBI using IMRT
in a 1:1 ratio. Allocation was performed
with a computer-generated sequence using
a randomly permuted block design, with-
out any stratification of main prognostic
factors”, page 453, paragraph 1
We judged this at low risk of bias
Allocation concealment (selection bias) Low risk Quote: “The random sequence was kept by
an external centre (local Oncological Cen-
tre for Departmental Reference, CORD).
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Livi 2015 (Continued)
The clinicians were required to query it ev-
ery time an eligible patient had provided
written informed consent to determine the
allocation arm”, page 453, paragraph 1
We judged this at low risk of bias
Blinding of participants and personnel
(performance bias) Objective outcomes
Low risk Quote: “Clinicians, investigators and the
patients themselves were aware of the arm
assignment”, page 453, paragraph 1
Blinding would have been difficult in view
of the 2 very obviously different treatments,
we judged this domain at low risk of bias
Blinding of participants and personnel
(performance bias) Subjective outcomes
Low risk Quote: “Clinicians, investigators and the
patients themselves were aware of the arm
assignment”, page 453, paragraph 1
Blinding would have been difficult in view
of the 2 very obviously different treatments,
we judged this domain at low risk of bias
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Clinicians and investigators were not
blinded to treatment arm, but the pre-spec-
ifiedmammographic follow-upwould have
reduced the risk of bias related to the pri-
mary outcome
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Quote: “mammography was annually pro-
grammed”, page 454, paragraph 13
The clinicians and investigators were not
blinded to treatment arm, which makes as-
sessment of subjective outcomes at high
risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk No exclusions or attrition reported, so we
judged this domain at low risk of bias
Selective reporting (reporting bias) Unclear risk We did not review the protocol, so judged
this domain at unclear risk of bias
Other bias Low risk We did not identify any other sources of
bias
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Polgár 2007
Methods RCT
Single-centre trial
Country: Hungary
Accrual dates July 1998 to May 2004
Median follow-up: 10.2 years
Participants 258 women with invasive breast cancer
Inclusion criteria: wide excision with negative margins, unifocal tumour, tumour size <
20 mm, clinically or pathologically N0, or single microscopic nodal metastasis (> 0.2
mm and < 2.0 mm), i.e. pT1N0-1miM0, Grade I or II
Exclusion criteria: bilateral breast cancer, prior unilateral or contralateral breast cancer,
concomitant or previous other malignancies, invasive lobular cancer, pure ductal or
lobular cancer in situ (pTis). After 2001, women aged < 40 years excluded
Mean age 58-59 years (given for each arm)
Interventions Experimental arm: PBI; 88/128 women had 7 × 5.2 GyHDRmulti-catheter brachyther-
apy and 40/128 women unsuitable for HDR had 50 Gy/25 fractions electron beam RT
to partial breast
Control arm: 50 Gy/25 fractions WBRT (130 women)
Surgery: wide excision (resection of tumour with ≥ 1 cm macroscopic free margin).
Cavity marked with titanium clips
Central pathology review performed
Systemic therapy given according to institutional protocol
Baseline mammography was performed at 6 months after RT then annually. Women
were seen every 3 months in the first year, then once every 6 months
Outcomes Primary:
1. Local recurrence in the ipsilateral breast at 5 years
2. Cosmetic outcome (using the Harvard cosmetic score; Table 1)
Secondary:
1. Overall survival
2. Toxicity - late toxicity will be reported elsewhere
3. Cause-specific mortality (deaths due to breast cancer at 5 years)
4. Distant metastasis-free survival at 5 years
5. Relapse-free survival at 5 years
6. Subsequent mastectomy (ipsilateral partial mastectomy, modified radical
mastectomy or radical mastectomy)
7. Compliance, defined as the number of women who commence treatment with
PBI/APBI or conventional EBRT and complete the treatment course
Notes Early stopping at 258 women enrolled because another multicentred trial commenced
LR defined as any detection of cancer in the treated breast, confirmed histologically. An
“elsewhere breast failure” defined as ipsilateral (LR) ≥ 2 cm from the clips. All other LR
classified as true recurrence or marginal miss
Cosmetic score Harvard criteria, scored by treating radiation oncologist and chief inves-
tigator at analysis date (June to August 2006). In case of discrepancy, worst score used
for analysis
Event-free intervals defined as time between date of surgery and date of event or last
follow-up
41Partial breast irradiation for early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Polgár 2007 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “were randomised”. Polgár 2007,
page 694, paragraph 3
Quote: “randomly allocated to treatment
options by a sealed envelope system in
blocks of 10”
Randomization was done by the main in-
vestigator (C.P.) Polgár 2007, page 695,
paragraph 2
The trial was likely to have been random-
ized
Allocation concealment (selection bias) Unclear risk Quote: “randomly allocated to treatment
options by a sealed envelope system in
blocks of 10”. Polgár 2007, page 695, para-
graph 2
Allocation concealment appears to have
beendone, although the descriptionwas in-
complete, which contributed to the judge-
ment of unclear bias risk
Blinding of participants and personnel
(performance bias) Objective outcomes
Low risk Participants: not mentioned, unlikely to
have been done
Quote: “Blinding of physicians performing
treatments and follow-up of patients was
not possible for technical reasons”. Polgár
2007, page 695, paragraph 2
Physicians: not done
Quote: “Blinding of physicians performing
treatments and follow-up of patients was
not possible for technical reasons”. Polgár
2007, page 695, paragraph 2
We judged this domain at low risk of bias
Blinding of participants and personnel
(performance bias) Subjective outcomes
Low risk Participants: not mentioned, unlikely to
have been done
Quote: “Blinding of physicians performing
treatments and follow-up of patients was
not possible for technical reasons”. Polgár
2007, page 695, paragraph 2
Physicians: not done
Quote: “Blinding of physicians performing
treatments and follow-up of patients was
not possible for technical reasons”. Polgár
2007, page 695, paragraph 2
We judged this domain at low risk of bias
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Polgár 2007 (Continued)
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Participants: not mentioned, unlikely to
have been done
Quote: “Blinding of physicians performing
treatments and follow-up of patients was
not possible for technical reasons”. Polgár
2007, page 695, paragraph 2
Physicians: not done, but in view of pre-
specified follow-up protocol, with regu-
lar mammography, unlikely to have intro-
duced bias
Quote: “Patients were seen every three
months in the first two years after RT and
every six months thereafter. Baseline mam-
mography was performed six months after
completion of RT and yearly thereafter”.
Polgár 2007, page 697, paragraph 6
Quote: “Blinding of physicians performing
treatments and follow-up of patients was
not possible for technical reasons”. Polgár
2007, page 695, paragraph 2
Quote: “Local recurrence...proved by his-
tological confirmation in every case”.
Polgár 2007, page 697, paragraph 6
Assessors: not done
Unlikely to be a source of bias in view of
the pre-specified schedule for follow-up vis-
its and investigations. Local recurrence re-
quired biopsy confirmation, which would
reduce the risk of bias in evaluation of this
outcome
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Participants: not mentioned, unlikely to
have introduced bias
Physicians: notmentioned,may be a source
of bias
Assessors: not mentioned, unlikely to have
been done, this is potentially a source of
bias
Quote: “Cosmetic outcome scored inde-
pendently by treating radiation oncologist
and the main investigator…in the case of
discrepancy, the worse cosmetic score was
used for analysis”. Polgár 2007, page 697,
paragraph 5
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions: none
Attrition: 0 in experimental group, 2 in
control group (declined follow-up at 18
and 22 months postoperatively)
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Polgár 2007 (Continued)
Selective reporting (reporting bias) Unclear risk Outcomes in methods section:
1. Primary: local recurrence at 5 years
2. Differences in cosmetic outcome
Outcomes reported in paper:
1. LR
2. LR-FR at 5 years
3. 5-year actuarial LR rate, true
recurrence and marginal miss
4. Overall survival at 5 years
5. Cancer-specific survival at 5 years
6. Distant metastasis-free survival at 5
years
7. Disease-free survival at 5 years
8. Probability of developing
contralateral cancer at 5 years
9. Salvage therapy
10. Modified radical mastectomy rate
11. Cosmetic outcome
Outcomes in methods and protocol: pro-
tocol not reviewed
Other bias Low risk Trial stopped early (the trial enrolled 258
women of a planned sample size of 570
participants) because of a competing trial,
GEC-ESTRO, started recruiting
RAPID
Methods Phase III RCT; stratified for age, tumour histology, tumour size, adjuvant hormonal
therapy and clinical centre
Country: Canada, Australia, New Zealand
Median follow-up: 36 months
Participants Women aged ≥ 40 years with new diagnosis of DCIS or with microscopically clear
margins after BCS of non-invasive or invasive disease (or no residual disease on re-
excision). Negative axillary nodal involvement including micrometastasis (> 0.2 mm or
positive cells only identified on IHC as determined by sentinel node biopsy; axillary
node dissection; or clinical examination for DCIS only. Tumour size ≤ 3 cm
Interventions Experimental arm: APBI (3D-CRT: 38.5 Gy in 10 fractions, bd over 5-8 days. 6-8 hour
gap between doses required)
Control arm: WBRT (42.5 Gy in 16 fractions daily over 22 days). Women with large
breast size: 50 Gy in 25 fractions over 25 days. Boost 10 Gy in 4 or 5 fractions over 4-
7 days is permitted for those women deemed at moderate to high risk of LR as per local
cancer centre guidelines
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RAPID (Continued)
Outcomes Primary:
1. Ipsilateral breast tumour recurrence (defined as recurrent invasive or in situ cancer
in the ipsilateral breast including the axillary tail)
Secondary:
1. Adverse cosmetic outcome
2. Disease-free survival
3. Event-free survival
4. Overall survival
5. Radiation toxicity
6. Quality of life
7. Cost effectiveness
Notes QA: extensive QA processes (credentialling, real-time and post-hoc plan review)
NCT00282035
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “were randomly assigned using a
telephone-based central minimization pro-
cedure”
Thiswas deemed an adequatemethodof se-
quence generation and the domain judged
at low risk of bias
Allocation concealment (selection bias) Unclear risk The sequence generation was described
as “telephone-based central minimisation
procedure”, inadequate details were pro-
vided, so we deemed this at unclear risk of
bias
Blinding of participants and personnel
(performance bias) Objective outcomes
Low risk For technical reasons, blinding of partici-
pants and personnel was not possible, but
is unlikely to have introduced bias
Blinding of participants and personnel
(performance bias) Subjective outcomes
Low risk For technical reasons, blinding of partici-
pants and personnel was not possible, but
is unlikely to have introduced bias
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Bilateral mammograms were per-
formed annually”
We judged this domain at low risk of bias,
because the mammography interval was
pre-specified and this ensures the primary
objective outcome (IBTR) was at low risk
of bias
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RAPID (Continued)
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: “..addition to nurse and patient as-
sessments, cosmesis was assessed by two
panels of three radiation oncologists us-
ing the digital photographs. The physicians
hadbreast cancer expertise andwere trained
to use the EORTC Cosmetic Rating Sys-
tem. After demonstrating good agreement
in the ability to identify adverse cosmesis
(0.71; Appendix, online only), each panel
reviewed half of the available 3-year post-
RT photo- graphs. The panels, blinded to
treatment allocation, provided one consen-
sus global cosmetic score for each patient
(Appendix, online only)”
It was not stated whether the trained
nurses evaluating the cosmetic outcome
were blinded to treatment arm; however,
the physician reviewers were blinded to
treatment arm, so we judged this at low risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Because this was an interim report, we were
unable to assess the number of exclusions or
attrition, so judged the domain at unclear
risk of bias
Selective reporting (reporting bias) Unclear risk Because this was an interim report, we
judged this domain at unclear risk of bias
Other bias Unclear risk No other sources of bias noted
Rodriguez
Methods Phase III RCT (relative non-inferiority)
Country: Spain
Accrual dates: not stated, started accrual 2004
Median follow-up: 60 months
Participants 102 women with invasive ductal carcinoma (pT1-2cNO MO), aged ≥ 60 years old,
unifocal tumour, ≤ 3 cm, Grade I or II
Interventions Experimental arm: PBI/APBI delivered by 3D-CRT at 48Gy/24 fractions ± 10 Gy boost
(depending on risk factors for local recurrence). 51 women
Control arm: conventional WBRT at 48 Gy/24 fractions ± 10 Gy boost (51 women)
Outcomes 1. Local control
2. Dosimetry and toxicity (using RTOG CTC)
3. Skin elasticity measured using a dedicated device
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Rodriguez (Continued)
Notes QA: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed by
a computer-generated, randomized list”,
page 1052, paragraph 5
This was an adequate method of sequence
generation, so we judge this domain at low
risk of bias
Allocation concealment (selection bias) Unclear risk Allocation concealment was not clearly de-
scribed, so we judged this domain at un-
clear risk of bias
Blinding of participants and personnel
(performance bias) Objective outcomes
Low risk Binding of participants and personnel was
not mentioned, and probably not done, as
it would have seen difficult in view of the
technical aspects of the 2 intervention arms.
We judged this domain at low risk of bias
Blinding of participants and personnel
(performance bias) Subjective outcomes
Low risk Binding of participants and personnel was
not mentioned, and probably not done, as
it would have seen difficult in view of the
technical aspects of the 2 intervention arms.
We judged this domain at low risk of bias
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Quote: “Baseline mammography was per-
formed 6 months after the completion of
radiation therapy and yearly thereafter. Ab-
dominal ultrasonography, chest radiogra-
phy, and blood tests were performed at least
annually. Local recurrence was defined as
any histologically confirmed cancer tissue
in the treated breast”, page 1053, paragraph
2
Because the mammography intervals were
pre-specified and local recurrence required
histological confirmation, the lack of blind-
ing on the part of the outcome assessors was
not judged at high risk of bias
Blinding of outcome assessment (detection
bias)
Subjective outcomes
High risk Quote: “Cosmetic results were evaluated
according to the Harvard criteria at base-
line and at each follow-up visit by the treat-
ing radiation oncologist”, page 1053, para-
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Rodriguez (Continued)
graph 5
All participants who had a minimum of 1
year follow-up were asked to rate cosmetic
results on a 10-point scale, as follows: excel-
lent (10-9), good (8-6), fair (5-4), or poor
(3-1)
Acute, late RT toxicity and cosmesis were
evaluated by the treating physician (not
blinded, so at risk of bias). However, partic-
ipants also rated the cosmetic outcome as
well. Despite this participant-reported out-
come, we judged this outcome at high risk
of bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Because this was an interim report, we
judged it at unclear risk of bias
Selective reporting (reporting bias) Unclear risk Because this was an interim report, we
judged it at unclear risk of bias
Other bias Unclear risk Because this was an interim report, we
judged it at unclear risk of bias
TARGIT
Methods Multicentre international randomized non-inferiority Phase III trial
Accrual: March 2000 - data lock 2 May 2010
Country: 11 countries (across Europe, UK, US and Australia)
Median follow-up: 29 months (1222/3451 (35%)) had 60 months’ follow-up
Participants 1113 women aged ≥ 45 years, with T1 and small T2N0-1M0 invasive breast cancer,
suitable for BCS, available for 10 years’ follow-up
Interventions Experimental arm: 1 fraction of RT given intraoperatively (using Intrabeam); 50 kV 20
Gy/fraction at 2mm beyond surface of 1.5-5.0 cm spherical applicator placed in excision
cavity
Control arm: standard postoperative RT (40-56 Gy ± 10-16 Gy boost)
Outcomes Primary:
1. Pathologically confirmed local relapse within the treated breast
Secondary:
1. Site of relapse within the breast
2. Relapse-free survival and overall survival
3. Local toxicity
4. Local morbidity
Notes Intrabeam uses low kilovolt x-rays to deliver 20 Gy at the surface of the tumour bed,
attenuating to 5-7 Gy at 1 cm. QA: training and auditing by member of International
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TARGIT (Continued)
Standards Organisation (ISO) required before centre could join
NCT00983684, ISCTN 34086741, ISRCTN 34086741, RECNo. 99/0307, UKCRN
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation scheduleswere
generated centrally by computer (securely
kept in trial centres in Perth for Australian
centres and London, UK, for all other cen-
tres)”, page 94, paragraph 1
Allocation concealment (selection bias) Low risk Quote: “Patients were randomly assigned
in a 1:1 ratio…with blocks stratified by
centre”. Abstract, page 1, paragraph 2
Quote: “The randomisation scheduleswere
generated centrally by computer (securely
kept in trial centres in Perth for Australian
centres, and London, UK for all other cen-
tres). Requests for randomisation were via
telephone or fax to the trials office (Perth
or London), where a trained member of
staff checked patient eligibility. Treatment
was allocated from a pre-printed randomi-
sation schedule available to authorised staff
only. Written confirmation of randomisa-
tion was sent by fax to the site”. Methods,
page, 94, paragraph 1
This trial was likely to have had adequate
allocation concealment
Blinding of participants and personnel
(performance bias) Objective outcomes
Low risk Participants: “Neither patients nor investi-
gators or their teams were masked to treat-
ment assignment”. Abstract, page 1, para-
graph 2
Physicians: “Neither patients nor investiga-
tors or their teams were masked to treat-
ment assignment”. Abstract, page 1, para-
graph 2
Quote: “Individual centres were unblinded
to treatment given in their own centres, but
they were not given access to these data for
other sites”. Methods, page 1, paragraph 3
Quote: “Patient assessments were sched-
uled at entry”
Because of the nature of the intervention,
it was not possible to blind the women par-
ticipating or the personnel involved in their
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TARGIT (Continued)
care, this is not likely to have resulted in
bias. Because the patient assessments were
scheduled at trial entry with pre-specified
times for follow-up visits this is likely to
have reduced the risk of bias from the lack
of blinding of personnel
Blinding of participants and personnel
(performance bias) Subjective outcomes
Low risk Participants: “Neither patients nor investi-
gators or their teams were masked to treat-
ment assignment”. Abstract, page 1, para-
graph 2
Physicians: “Neither patients nor investiga-
tors or their teams were masked to treat-
ment assignment”. Abstract, page 1, para-
graph 2
Quote: “Individual centres were unblinded
to treatment given in their own centres, but
they were not given access to these data for
other sites”. Methods, page 4, paragraph 3
Quote: “Patient assessments were sched-
uled at entry”
Because of the nature of the intervention,
it was not possible to blind the women par-
ticipating or the personnel involved in their
care, this is not likely to have resulted in
bias. Because the participant assessments
were scheduled at trial entry with pre-spec-
ified times for follow-up visits this is likely
to have reduced the risk of bias from the
lack of blinding of personnel
Blinding of outcome assessment (detection
bias)
Objective outcomes
Low risk Participants: not relevant
Physicians: not relevant
Assessors: “Patient’s assessments were
scheduled at entry, 3 months and 6
months”, page 94, paragraph 4
This means the risk of lead time bias was
reduced
Quote: “We recommend that mammogra-
phy of the ipsilateral breast occurs annually
and of the contralateral breast at least every
three years”. TARGIT protocol, 7.1 page
25
Quote: “Confidential unblinded reports
for the DMC, and blinded reports for the
ISO were produced by the trial statistician.
Unblinded analyses were done according
to a prespecified statistical analysis plan”.
Methods, page 4, paragraph 3
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If there were pre-specified time intervals for
mammography, this would have reduced
the risk of bias for detection of the primary
endpoint: local relapse
Blinding of outcome assessment (detection
bias)
Subjective outcomes
Low risk Quote: “The secondary outcome measure
of local toxicity, or morbidity was assessed
from data recorded on the complications
formwhich contained a prespecified check-
list”, page 94, paragraph 3
It was not stated who assessed the subjec-
tive outcomes, however, we know: “Neither
patients nor investigators or their teams
weremasked to treatment assignment”. Ab-
stract, page 1, paragraph 2
The blinding of outcome assessors was not
reported, this does mean that there was risk
of biaswith assessment of toxicity; however,
the use of a pre-specified form would help
to reduce bias because the data would be
collected for all women
Quote: “digital photographs...were as-
sessed, blinded to treatment arm” (Kesht-
gar et al. Journal of Clinical Oncology Vol.
28. 2010:7S, abstract 570)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All randomised patients were in-
cluded in the intention-to-treat analysis”.
Abstract, page 1, paragraph 2
Quote: “When displaying the results, we
restricted the duration of follow up to four
years...since fewer than 420 (< 20%) pa-
tients had follow up beyond this point”,
page 95, paragraph 4
Because the outcomes were reported with
a follow-up duration of 4 years, this does
mean there is a high risk of bias because
they reported on < 20% of the participants
Selective reporting (reporting bias) Low risk Outcomes specified in the protocol:
1. Local tumour control
2. Site of relapse within the breast
3. Relapse-free survival
4. Overall survival
5. Local toxicity and morbidity
6. Cosmesis, participant satisfaction,
health economics, participant preference
will be the subject of a sub-protocol
Outcomes specified in methods:
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1. Primary:
i) “Pathologically confirmed local
relapse within the treated breast”, page 94,
paragraph 5
2. Secondary:
i) Prospectively collected local
toxicity or morbidity (checklist included
haematoma, seroma, wound infection,
skin breakdown, delayed wound healing)
ii) RTOG Grade III/IV dermatitis
iii) Telangiectasia
iv) Pain in irradiated field or other
v) “To assess extent of local
surgery we analysed specimen weight,
margin status and re-operation for
margins”, page 95, paragraph 1
Outcomes reported in paper:
1. Median amount of tissue resected
2. Re-excision rates
3. Any complication
4. Clinically significant complications
5. RTOG toxicity score of III/IV
6. Major toxicity rate
7. Axillary recurrences
8. Uncontrolled local recurrences
9. Local recurrences at 4 years
The authors stated that, “no changes were
made to trial outcomes after commence-
ment of the trial”
The outcomes pre-specified in the proto-
col were not all reported, this probably re-
flects the short follow-up duration, but we
consider these outcomes are likely to be re-
ported in future publications
Other bias High risk Short duration of follow-up puts the out-
comes reported at high risk of bias
3D-CRT: 3-dimensional conformal radiotherapy; APBI: accelerated partial breast irradiation; BCS: breast-conserving surgery; bd: twice
a day; DCIS: ductal carcinoma in situ; DMC: data monitoring committee; EBRT: external beam radiotherapy; Gy: Gray; HDR:
high-dose-rate; IBRT: ipsilateral breast tumour recurrence; IHC: immunohistochemistry; IMRT: intensity-modulated radiotherapy;
LENT-SOMA: late effects in normal tissues - subjective, objective, management and analytic; LR: local recurrence; M: metastases;
MeV: mega electron volts; N: lymph node; PBI: partial breast irradiation; PDR: pulsed-dose-rate; QA: quality assurance; RCT:
randomized controlled trial; RNI: regional nodal irradiation; RT: radiotherapy; RTOG CTC: Radiation Therapy Oncology Group
Common Toxicity Criteria; WBRT: whole breast radiotherapy.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dodwell 2005 RCT, but used surgical, systemic management and RT techniques that were not consistent with contemporary
practice
NCT00892814 Phase II RCT
NCT01185132 PBI used in both study arms
NCT01928589 PBI used in both study arms
NCT02003560 PBI used in both study arms
Ribeiro 1993 RCT, but used surgical, systemic management and RT techniques that were not consistent with contemporary
practice
TARGIT-B WBRT used in both study arms
TROG Feasibility study and not an RCT
PBI: partial breast irradiation; RCT: randomized controlled trial; RT: radiation treatment; WBRT: whole breast radiotherapy.
Characteristics of studies awaiting assessment [ordered by study ID]
NCT02375048
Methods Randomized Phase II trial
Participants Women aged 55-70 years
Inclusion criteria:
1. aged 55-70 years
2. Tumour size ≤ 2 cm
3. pN0 (SN biopsy or ALND)
4. ER/PgR positive
5. Margins > 5 mm (either at initial surgery or at re-excision)
6. Clips placed in the surgical bed (minimum of 4 clips)
7. Unicentric only
8. No lympho-vascular invasion
9. Any grade
10. No extensive intraductal component (> 25%)
11. Written informed consent
Exclusion criteria:
1. Prior thoracic radiotherapy
2. Oncoplastic surgery/no clips in the surgical bed
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NCT02375048 (Continued)
3. Multicentric cancer
4. Autoimmune disease, vasculitis, collagenopathy or scleroderma that may predispose to late sequelae
Interventions Experimental arm: APBI
APBI was delivered at a dose of 30 Gy in 5-6 Gy/day fractions over 10 days (every other day) with IGRT at each
treatment
Control arm: hypofractionated WBRT
Dose prescription was 40.5 Gy to planning target volume whole breast (PTV WB) and 48.0 Gy to PTV boost in
15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2 Gy/fraction for each PTV,
respectively. Daily IGRT were generated before each treatment session in each participant to verify the set-up
Outcomes Primary:
1. Toxicity will be measured with CTCAE v.4.0
2. Cosmesis will be measured with Harvard scale
Secondary:
1. Rate of local control
2. Disease-free survival
3. Overall survival
4. Quality of life questionnaire
Notes Randomized study on postmenopausal women with early-stage breast cancer: adjuvant hypofractionated WBI vs.
APBI. Starts 2015, 700 women
Email: marta.scorsetti%40humanitas.it
ALND: axillary lymph node dissection; APBI: accelerated partial breast irradiation; ER: oestrogen receptor; GTV: gross tumour volume;
Gy: Gray; IGRT: image-guided radiotherapy; N: lymph node; PgR: progesterone receptor; PTV: planning target volume; SN:
sentinel node biopsy; WBI: whole breast irradiation.
Characteristics of ongoing studies [ordered by study ID]
IMPORT
Trial name or title Randomized Trial Testing Intensity Modulated and Partial Organ Radiotherapy After Breast Conservation
Surgery for Early Breast Cancer
Methods Randomized, Phase III multicentre trial
Participants Women aged > 50 years, with invasive breast cancer pT1-2pN0, who have had BCS with negative margins
(≥ 2 mm) who have < 1% annual risk of local recurrence
Interventions Experimental arm 1: reduced WBRT and standard PBI once daily on days 1-5 for 3 weeks
IMRT
Arm 1: 40 Gy/15 fractions
Arm 2: 40 Gy/15 fractions + integrated boost to WB 36 Gy/15 fractions
Experimental arm 2: PBI daily on days 1-5 for 3 weeks
Control: standard WBRT day 1-5 for 3 weeks
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IMPORT (Continued)
Outcomes Primary: local tumour control in the ipsilateral breast
Secondary: location of tumour relapse, contralateral primary breast cancer, regional or distant metastases, late
adverse effects in normal tissues (photographic, physician and participant assessments), quality of life, cost-
effectiveness
Starting date October 2006
Contact information J Yarnold, Royal Marsden, London
Notes NCT00814567
CSDR0000629765, ICR-IMPORT-LOW, ICR-CTSU/2006/10001, ISCTN12852634, EU-20896
Target volume: 6 pairs of clips in cavity = CTV + 10 mm = PTV
IRMA
Trial name or title Breast Cancer with Low Risk of Local Recurrence: Partial and Accelerated Radiation with Three-Dimensional
Conformal Radiotherapy (3DCRT) Vs. Standard Radiotherapy After Conserving Surgery (Phase III Study)
Methods Multicentre Phase III controlled randomized, unblinded study of non-inferiority
Participants Women aged ≥ 49 years, ECOG 0-2, undergoing conservative breast surgery for invasive breast cancer,
pT1-2 (< 3 cm in diameter) pN0-N1 M0, unifocal, resection margins histologically negative (2 mm) at first
intervention or after subsequent widening
Interventions Experimental arm: 38.5 Gy total in 10 fractions (3.85 Gy per fraction), twice a day with an interval of at least
6 hours between the 2 fractions, for 5 consecutive working days of the sole cavity
Control arm: 50.0 Gy in 25 fractions (2 Gy per fraction), once a day for 5 days in the week RT of the entire
breast
Outcomes Primary: survival free of local ipsilateral recurrence as prime event
Secondary: global survival, loco-regional recurrence-free, distant recurrence-free, acute and late toxicity
(RTOG) and cosmetic result
Starting date -
Contact information Data Center Office
Clinical Trials Office, Integrated Department of Oncology and Hematology
Polyclinic Hospital, University of Modena and Reggio Emilia
R. D’Amico, G. Jovic, R. Vicini
Tel. 059 4223865
Email: Roberto.damico@unimore.it
Notes Study currently accruing participants. Target volume: GTV + 15 mm = CTV + 5 mm = PTV
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NSABP-B39/RTOG
Trial name or title A Randomised Phase II Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradi-
ation (PBI) for Women with Stage 0, I, or II Breast Cancer
Methods Randomized, multicentre Phase III trial
Participants Women aged > 18 years with histologically confirmedDCIS or invasive adenocarcinoma of the breast, negative
histological margins, no more than 3 axillary nodes involved, must have had BCS
Interventions Experimental arm: PBI 5 days per week for 5-7 weeks
Control arm: WBRT bd on 5 days over 5-10 days (50 Gy in 25 fractions at 1.8-2 Gy per fraction, optional
boost to 60-66 Gy)
Brachytherapy 34 Gy/10 fractions
MammoSite 34 Gy/10 fractions
3DCRT 38.5 Gy/10 fractions
Outcomes Primary: in-breast tumour recurrence
Secondary: survival, event-free survival, distant disease-free survival, quality of life and participant-reported
cosmesis, physician-reported cosmesis and toxicity
Starting date March 2005
Contact information Study chair: F Vicini, William Beaumont Hospital- Royal Oak Campus
J White, Medical College of Wisconsin
Notes NCT00103181
NSABP B-39/RTOG 0413, SWOG-NSABP-B-39
Collaborators: Southwest Oncology Group, National Cancer Institute, RTOG, National Surgical Adjuvant
Breast and Bowel Project
For brachytherapy and 3DCRT: cavity plus 15 mm = CTV + 10 mm = PTV
MammoSite: PTV = 10 mm expansion on balloon minus balloon volume
SHARE
Trial name or title Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (PBI/APBI) for
Breast Cancer (SHARE) Phase III Multicentric Trial Comparing Accelerated Partial Breast Irradiation (PBI/
APBI) Versus Standard or Hypofractionated Whole Breast Irradiation in Low Risk of Local Recurrence of
Breast Cancer
Methods Multicentre RCT
Participants Inclusion criteria:
1. Women aged ≥ 50 years
2. Menopausal status confirmed
3. Pathology confirmation of invasive carcinoma (all types)
4. Complete tumour removal and conservative surgery
5. Pathologic tumour size of invasive carcinoma ≤ 2 cm (including the in situ component) pT1
6. All histopathological grades
7. Clear lateral margins for the invasive and in situ disease (> 2 mm)
8. pN0 or pN(i+)
56Partial breast irradiation for early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
SHARE (Continued)
9. No metastasis
10. RT should be started > 4 weeks and < 12 weeks after last surgery
11. Surgical clips (4 or 5 clips in the tumour bed)
12. No prior breast or mediastinal RT
13. ECOG 0-1
14. Information to the participant and signed informed consent
Exclusion criteria:
1. Multifocal invasive ductal carcinoma defined as the presence of ≥ 2 distinct tumours that are separated
by normal tissue or when the distance between the 2 lesions does not permit conservative surgery
2. Bilateral breast cancer
3. No or < 4 surgical clips in the tumour bed
4. Nodal involvement: pN1 (including micrometastasis, mi+), pN2, pN3
5. Metastatic disease
6. Internal mammary node involvement or supraclavicular lymph node involvement
7. Indication of chemotherapy or trastuzumab
8. Involved or close lateral margins for the invasive with or without in situ components (< 2 mm) AND
impossibility to re-operate or impossible to perform another conservative surgery
9. Women with known BRCA1 or BRCA2 mutations
10. Previous mammoplasty
11. Previous homolateral breast or mediastinal irradiation, or both
12. Previous invasive cancer (except basocellular epithelioma or in situ carcinoma of the cervix)
13. No geographical, social or psychological reasons that would prevent study follow-up
Interventions Experimental arm: APBI
3D-CRT
40 Gy/10 fractions
Tumour bed 40 Gy in 10 fractions, 2 fractions of 4 Gy per day in 5-7 days. PBI/APBI using 3D-CRT
technique, in 5 days, 40 Gy to the tumour bed
Control arm: standard or hypofractionated radiotherapy
Outcomes Primary:
1. Rate of local recurrence
Secondary:
1. Ipsilateral breast recurrence-free survival
2. Nodal regional recurrence-free survival
3. Distant recurrence-free survival
4. Disease-specific survival
5. Overall survival
6. Toxicities: measurement of the rate and type of toxicity (acute and late toxic effects)
7. Cosmetic: comparison of the cosmetic result (according to both the physician and the participant)
8. Quality of life and satisfaction
9. Medico-economic study
Starting date October 2010
Contact information Jerome Lemonnier, PhD; Tel: +33 1 7193 6702; Email: j-lemonnier@unicancer.fr
Notes
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3D-CRT: 3-dimensional conformal radiotherapy; APBI: accelerated partial breast irradiation; BCS: breast-conserving surgery; bd: twice
a day; CTV: clinical target volume; DCIS: ductal carcinoma in situ; ECOG: Eastern Cooperative Oncology Group; ER: oestrogen
receptor; GTV: gross tumour volume; Gy: Gray; IGRT: image-guided radiotherapy; IMRT: intensity-modulated radiotherapy;
M: metastases; N: lymph node; PBI: partial breast irradiation; PgR: progesterone receptor; PTV: planning target volume; RCT:
randomized controlled trial; RT: radiotherapy; RTOG: Radiation Therapy Oncology Group; SN: sentinel node biopsy; WB: whole
breast; T: tumour; WBRT: whole breast radiotherapy.
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D A T A A N D A N A L Y S E S
Comparison 1. Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast
radiotherapy (WBRT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Local recurrence-free survival 6 6820 Hazard Ratio (95% CI) 1.62 [1.11, 2.35]
1.1 2.4 years’ median
follow-up
1 3451 Hazard Ratio (95% CI) 2.05 [1.00, 4.21]
1.2 5 years’ follow-up 4 3111 Hazard Ratio (95% CI) 2.50 [1.21, 5.15]
1.3 10 years’ follow-up 1 258 Hazard Ratio (95% CI) 1.09 [0.63, 1.89]
2 Cosmesis, physician-reported 5 1720 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [1.17, 1.95]
3 Overall survival 5 6718 Hazard Ratio (95% CI) 0.90 [0.74, 1.09]
4 Acute radiotherapy (RT) skin
toxicity
2 608 Odds Ratio (M-H, Fixed, 95% CI) 0.04 [0.02, 0.09]
5 Late RT skin toxicity 2 608 Odds Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.39]
6 Fat necrosis 3 1319 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [1.02, 2.43]
7 ’Elsewhere primary’ 3 3009 Odds Ratio (M-H, Fixed, 95% CI) 3.97 [1.51, 10.41]
8 Cause-specific survival 5 6718 Hazard Ratio (95% CI) 1.08 [0.73, 1.58]
9 Distant metastasis-free survival 4 3267 Hazard Ratio (95% CI) 0.94 [0.65, 1.37]
10 Relapse-free survival 3 3811 Hazard Ratio (95% CI) 1.36 [0.88, 2.09]
11 Loco-regional recurrence-free
survival
2 3553 Hazard Ratio (95% CI) 1.80 [1.00, 3.25]
12 Mastectomy 3 4817 Odds Ratio (M-H, Fixed, 95% CI) 1.20 [0.77, 1.87]
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Analysis 1.1. Comparison 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI)
versus whole breast radiotherapy (WBRT), Outcome 1 Local recurrence-free survival.
Review: Partial breast irradiation for early breast cancer
Comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)
Outcome: 1 Local recurrence-free survival
Study or subgroup PBI/APBI WBRT Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 2.4 years’ median follow-up
TARGIT 23/1721 11/1730 27.2 % 2.05 [ 1.00, 4.21 ]
Subtotal (95% CI) 1721 1730 27.2 % 2.05 [ 1.00, 4.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
2 5 years’ follow-up
ELIOT 21/651 4/654 12.3 % 7.19 [ 2.47, 20.96 ]
GEC-ESTRO 9/633 5/551 11.7 % 1.57 [ 0.53, 4.69 ]
Livi 2015 0/260 3/260 2.7 % 0.16 [ 0.02, 1.53 ]
Rodriguez 0/51 0/51 Not estimable
Subtotal (95% CI) 1595 1516 26.7 % 2.50 [ 1.21, 5.15 ]
Heterogeneity: Chi2 = 10.14, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 2.48 (P = 0.013)
3 10 years’ follow-up
Polg r 2007 7/128 6/130 46.1 % 1.09 [ 0.63, 1.89 ]
Subtotal (95% CI) 128 130 46.1 % 1.09 [ 0.63, 1.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 100.0 % 1.62 [ 1.11, 2.35 ]
Heterogeneity: Chi2 = 13.90, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Chi2 = 3.76, df = 2 (P = 0.15), I2 =47%
0.001 0.01 0.1 1 10 100 1000
Favours PBI/APBI Favours WBRT
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Analysis 1.2. Comparison 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI)
versus whole breast radiotherapy (WBRT), Outcome 2 Cosmesis, physician-reported.
Review: Partial breast irradiation for early breast cancer
Comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)
Outcome: 2 Cosmesis, physician-reported
Study or subgroup PBI/APBI WBRT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Livi 2015 0/246 2/260 2.5 % 0.21 [ 0.01, 4.39 ]
Polg r 2007 24/125 43/116 37.4 % 0.40 [ 0.23, 0.72 ]
RAPID 140/399 61/367 42.8 % 2.71 [ 1.92, 3.82 ]
Rodriguez 12/51 8/51 6.3 % 1.65 [ 0.61, 4.47 ]
TARGIT 12/55 13/50 11.0 % 0.79 [ 0.32, 1.95 ]
Total (95% CI) 876 844 100.0 % 1.51 [ 1.17, 1.95 ]
Total events: 188 (PBI/APBI), 127 (WBRT)
Heterogeneity: Chi2 = 34.47, df = 4 (P<0.00001); I2 =88%
Test for overall effect: Z = 3.14 (P = 0.0017)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PBI/APBI Favours WBRT
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Analysis 1.3. Comparison 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI)
versus whole breast radiotherapy (WBRT), Outcome 3 Overall survival.
Review: Partial breast irradiation for early breast cancer
Comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)
Outcome: 3 Overall survival
Study or subgroup PBI/APBI WBRT Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
ELIOT 34/651 31/654 15.6 % 1.10 [ 0.67, 1.81 ]
GEC-ESTRO 27/633 32/551 14.8 % 0.66 [ 0.39, 1.10 ]
Livi 2015 1/260 7/260 0.9 % 0.17 [ 0.02, 1.39 ]
Polg r 2007 25/128 23/130 47.5 % 1.05 [ 0.79, 1.40 ]
TARGIT 37/1721 51/1730 21.3 % 0.72 [ 0.47, 1.10 ]
Total (95% CI) 100.0 % 0.90 [ 0.74, 1.09 ]
Heterogeneity: Chi2 = 6.68, df = 4 (P = 0.15); I2 =40%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PBI/APBI Favours WBRT
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Analysis 1.4. Comparison 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI)
versus whole breast radiotherapy (WBRT), Outcome 4 Acute radiotherapy (RT) skin toxicity.
Review: Partial breast irradiation for early breast cancer
Comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)
Outcome: 4 Acute radiotherapy (RT) skin toxicity
Study or subgroup PBI/APBI WBRT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Livi 2015 5/246 98/260 74.9 % 0.03 [ 0.01, 0.09 ]
Rodriguez 9/51 38/51 25.1 % 0.07 [ 0.03, 0.19 ]
Total (95% CI) 297 311 100.0 % 0.04 [ 0.02, 0.09 ]
Total events: 14 (PBI/APBI), 136 (WBRT)
Heterogeneity: Chi2 = 1.37, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 9.10 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PBI/APBI Favours WBRT
Analysis 1.5. Comparison 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI)
versus whole breast radiotherapy (WBRT), Outcome 5 Late RT skin toxicity.
Review: Partial breast irradiation for early breast cancer
Comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)
Outcome: 5 Late RT skin toxicity
Study or subgroup PBI/APBI WBRT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Livi 2015 0/246 2/260 100.0 % 0.21 [ 0.01, 4.39 ]
Rodriguez 0/51 0/51 Not estimable
Total (95% CI) 297 311 100.0 % 0.21 [ 0.01, 4.39 ]
Total events: 0 (PBI/APBI), 2 (WBRT)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PBI/APBI Favours WBRT
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Analysis 1.6. Comparison 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI)
versus whole breast radiotherapy (WBRT), Outcome 6 Fat necrosis.
Review: Partial breast irradiation for early breast cancer
Comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)
Outcome: 6 Fat necrosis
Study or subgroup PBI/APBI WBRT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ELIOT 22/151 10/146 26.1 % 2.32 [ 1.06, 5.09 ]
Polg r 2007 26/127 26/129 61.7 % 1.02 [ 0.55, 1.87 ]
RAPID 12/399 4/367 12.2 % 2.81 [ 0.90, 8.80 ]
Total (95% CI) 677 642 100.0 % 1.58 [ 1.02, 2.43 ]
Total events: 60 (PBI/APBI), 40 (WBRT)
Heterogeneity: Chi2 = 3.89, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PBI/APBI Favours WBRT
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Analysis 1.7. Comparison 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI)
versus whole breast radiotherapy (WBRT), Outcome 7 ’Elsewhere primary’.
Review: Partial breast irradiation for early breast cancer
Comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)
Outcome: 7 ’Elsewhere primary’
Study or subgroup PBI/APBI WBRT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ELIOT 14/651 0/654 9.3 % 29.77 [ 1.77, 500.15 ]
GEC-ESTRO 3/633 4/551 81.3 % 0.65 [ 0.15, 2.92 ]
Livi 2015 3/260 0/260 9.4 % 7.08 [ 0.36, 137.78 ]
Total (95% CI) 1544 1465 100.0 % 3.97 [ 1.51, 10.41 ]
Total events: 20 (PBI/APBI), 4 (WBRT)
Heterogeneity: Chi2 = 7.67, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 2.80 (P = 0.0051)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PBI/APBI Favours WBRT
65Partial breast irradiation for early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI)
versus whole breast radiotherapy (WBRT), Outcome 8 Cause-specific survival.
Review: Partial breast irradiation for early breast cancer
Comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)
Outcome: 8 Cause-specific survival
Study or subgroup PBI/APB WBRT Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
ELIOT 23/651 20/654 41.0 % 1.20 [ 0.66, 2.18 ]
GEC-ESTRO 4/633 4/551 7.7 % 0.87 [ 0.22, 3.46 ]
Livi 2015 1/260 3/260 2.9 % 0.38 [ 0.04, 3.63 ]
Polg r 2007 6/128 10/130 14.4 % 0.78 [ 0.28, 2.15 ]
TARGIT 20/1721 16/1730 34.1 % 1.25 [ 0.65, 2.41 ]
Total (95% CI) 100.0 % 1.08 [ 0.73, 1.58 ]
Heterogeneity: Chi2 = 1.62, df = 4 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PBI/APBI Favours WBRT
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Analysis 1.9. Comparison 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI)
versus whole breast radiotherapy (WBRT), Outcome 9 Distant metastasis-free survival.
Review: Partial breast irradiation for early breast cancer
Comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)
Outcome: 9 Distant metastasis-free survival
Study or subgroup PBI/APBI WBRT Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
ELIOT 33/651 35/654 62.1 % 0.98 [ 0.61, 1.58 ]
GEC-ESTRO 5/633 5/551 9.1 % 0.86 [ 0.25, 2.97 ]
Livi 2015 3/260 4/260 6.3 % 0.88 [ 0.20, 3.96 ]
Polg r 2007 11/128 14/130 22.5 % 0.90 [ 0.41, 1.98 ]
Total (95% CI) 100.0 % 0.94 [ 0.65, 1.37 ]
Heterogeneity: Chi2 = 0.07, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PBI/APBI Favours WBRT
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Analysis 1.10. Comparison 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI)
versus whole breast radiotherapy (WBRT), Outcome 10 Relapse-free survival.
Review: Partial breast irradiation for early breast cancer
Comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)
Outcome: 10 Relapse-free survival
Study or subgroup PBI/APBI WBRT Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Polg r 2007 19/128 20/130 47.0 % 0.99 [ 0.53, 1.85 ]
Rodriguez 0/51 0/51 Not estimable
TARGIT 31/1721 17/1730 53.0 % 1.80 [ 1.00, 3.25 ]
Total (95% CI) 100.0 % 1.36 [ 0.88, 2.09 ]
Heterogeneity: Chi2 = 1.84, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PBI/APBI Favours WBRT
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Analysis 1.11. Comparison 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI)
versus whole breast radiotherapy (WBRT), Outcome 11 Loco-regional recurrence-free survival.
Review: Partial breast irradiation for early breast cancer
Comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)
Outcome: 11 Loco-regional recurrence-free survival
Study or subgroup PBI/APBI WBRT Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
Rodriguez 0/51 0/51 Not estimable
TARGIT 31/1721 17/1730 100.0 % 1.80 [ 1.00, 3.25 ]
Total (95% CI) 100.0 % 1.80 [ 1.00, 3.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.052)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PBI/APBI Favours WBRT
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Analysis 1.12. Comparison 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI)
versus whole breast radiotherapy (WBRT), Outcome 12 Mastectomy.
Review: Partial breast irradiation for early breast cancer
Comparison: 1 Partial breast irradiation (PBI)/accelerated partial breast irradiation (APBI) versus whole breast radiotherapy (WBRT)
Outcome: 12 Mastectomy
Study or subgroup PBI/APBI WBRT Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
GEC-ESTRO 1/633 0/551 1.5 % 2.62 [ 0.11, 64.34 ]
Polg r 2007 0/128 2/130 6.9 % 0.20 [ 0.01, 4.21 ]
TARGIT 42/1679 34/1696 91.7 % 1.25 [ 0.79, 1.98 ]
Total (95% CI) 2440 2377 100.0 % 1.20 [ 0.77, 1.87 ]
Total events: 43 (PBI/APBI), 36 (WBRT)
Heterogeneity: Chi2 = 1.59, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PBI/APBI Favours WBRT
A D D I T I O N A L T A B L E S
Table 1. Harvard cosmetic score
Cosmetic score
Excellent
Good
Fair
Poor
Table 2. Brachytherapy cosmetic score
Score Definition
Excellent Perfect symmetry, no visible distortion or skin changes and no visible catheter entry/exit sequelae
Good Slight skin distortion, retraction or oedema, any visible telangiectasia, any visible catheter entry/exit scar or mild hyper-
pigmentation
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Table 2. Brachytherapy cosmetic score (Continued)
Fair Moderate distortion of the nipple or breast symmetry,moderate hyperpigmentation, or prominent skin retraction, oedema
or telangiectasia
Poor Marked distortion, oedema, fibrosis or severe hyperpigmentation
Table 3. RTOG CTC acute skin toxicity
RTOG CTC Grade I Grade II Grade III Grade IV
Description Follicular, faint or dull ery-
thema / epilation / dry
desquamation / decreased
sweating
Tender or bright erythema,
patchymoist desquamation
/ moderate oedema
Confluent, moist desqua-
mation other than skin
folds, pitting oedema
Ulceration, haemorrhage,
necrosis
RTOG CTC: Radiation Therapy Oncology Group Common Toxicity Criteria.
Table 4. Fat necrosis
Grade Findings
0 No fat necrosis
1 Asymptomatic fat necrosis (only radiological or
cytological findings, or both)
2 Symptomatic fat necrosis not requiring medication
(palpable mass with or without mild pain)
3 Symptomatic fat necrosis requiring medication
(palpable mass with significant pain)
4 Symptomatic fat necrosis requiring surgical
intervention
Table 5. NCI CTC 3.0
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Induration
(subcutaneous fibrosis)
Increased density on pal-
pation
Mod-
erate increase in den-
sity, not interfering with
ADL;marked increase in
density and firmness on
palpation with or with-
out minimal retraction
Dysfunction interfering
with ADL; very marked
density, retraction or fix-
ation
-
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Table 5. NCI CTC 3.0 (Continued)
Telangiectasia Few Moderate Many and confluent -
Pain Pain mild, not interfer-
ing with function
Moderate pain;
pain or analgesics inter-
fering with function, but
not with ADL
Severe pain; pain or anal-
gesics interfering with
ADL
Disability
ADL: activities of daily living; NCI CTC: National Cancer Institute Common Toxicity Criteria.
Table 6. Radiotherapy doses prescribed
Trial PBI/APBI dose Fraction size
(Gy)
EQD2 PBI/
APBI
Control dose Fraction size
(Gy)
EQD2 Control
TARGIT 20 Gy at surface
of the applicator
(attenuated to 5-
7 Gy at 1 cm)
(APBI)
80 at cavity sur-
face
12.8 at 1 cm
80 Gy at cavity
surface
12.8 Gy at 1 cm
40-56 Gy/20-28
fractions ± 10-16
Gy boost
2 40-56 Gy ±
10-16 Gy
Livi 2015 30 Gy/5 daily
fractions EBRT
IMRT. 100% of
the PTVwas cov-
ered by 95%
of the prescribed
dose
6 75 Gy 50 Gy/25 frac-
tions + 10 Gy/5
fractions boost
2 50 + 10 = 60 Gy
RAPID 38.5 Gy/10 frac-
tions bd (with 6
hour gap)
Dose-evaluation
volume (that part
of PTV within
the breast) re-
ceived
95-107% of pre-
scription dose
3.85 74.1 Gy 50 Gy/25 frac-
tions or 42.5 Gy/
16 fractions ±
boost (10Gy/4-5
fractions)
based on criteria
such as young age
or close margins,
pre-specified by
centre
2 or 2.65 50 or 47.1 Gy
Rodriguez 37.5 Gy/10 frac-
tions bd (with 6
hour gap) (APBI)
. PTV covered
by ≥ 95% of
prescribed dose,
with < 105% hot
spot
3.75 71.22 Gy 48 Gy/24 frac-
tions ± 10 Gy/5
fractions boost
2 48 ± 10 = 48-58
Gy
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Table 6. Radiotherapy doses prescribed (Continued)
Polgár 2007 7 × 5.2 Gy HDR
(APBI) or 50Gy/
25 fractions
(PBI).
Women not suit-
able for
HDR had 6-15
MeV beam to tu-
mour bed plus 2
cm margin (field
size defined using
CT-planning or
simulation films)
5.2 or 2 53.6 Gy or 50Gy 50 Gy/25 frac-
tions (3D-CRT
was not used)
2 50 Gy
GEC-ESTRO 30.3 Gy/7 frac-
tions or 32 Gy/8
fractions
HDR twice daily
or 50Gy at 0.6-0.
8 Gy/hour pulses
(1 pulse per hour,
24 hours per day)
PDR
7-8 41.64-42.67 Gy 50.0-50.4 Gy to
a reference point
+ 10 Gy/5 frac-
tions boost. Elec-
tron dose was
prescribed to the
point of maxi-
mum dose
on the beam axis
(Dmax ), ensuring
the 85% isodose
encompassed the
tumour bed
1.8-2.0 48.72-50 + 10 =
58.72-60 Gy
ELIOT 21 Gy/1 fraction
at 90% using 6-9
MeV
21 131.2 Gy 50 Gy/25 frac-
tions + 10 Gy/
5 fractions boost
(using electrons)
2.0 50 + 10 Gy
3D-CRT: 3-dimensional conformal radiotherapy; APBI: accelerated partial breast irradiation; bd: twice daily; CT: computer tomog-
raphy; EBRT: external beam radiotherapy; EQD2: equivalent dose in 2 Gy fractions; Gy: Gray; HDR: high-dose-rate; IMRT:
intensity-modulated radiotherapy; MeV: mega electron volt; PBI: partial breast irradiation; PDR: pulsed-dose-rate; PTV: planning
target volume.
Table 7. Radiotherapy techniques
Trial RT technique
Polgár 2007 Interstitial brachytherapy (88/128)
EBRT using photons (40/128)
ELIOT intra-operative electrons
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Table 7. Radiotherapy techniques (Continued)
Livi 2015 EBRT (IMRT)
TARGIT intra-operative kV RT
RAPID EBRT
Rodriguez EBRT (3D-CRT)
3D-CRT: 3-dimensional conformal radiotherapy; EBRT: external beam radiotherapy; IMRT: intensity-modulated radiotherapy; RT:
radiotherapy.
A P P E N D I C E S
Appendix 1. The Cochrane Central Register of Controlled Trials (CENTRAL)
1. MESH DESCRIPTOR Breast Neoplasms EXPLODE ALL TREES
2. breast AND (cancer* OR tumour* OR tumor* OR neoplas*)
3. #1 OR #2
4. brachytherapy:MH
5. brachytherapy
6. partial breast
7. partial breast irradiation
8. whole breast irradiation
9. whole breast radiotherapy
10. less than whole breast rad$
11. high-dose-rate brachytherapy
12. acceleration partial breast irradiation
13. acceleration irradiation
14. tumour bed boost
15. sole tumour boost
16. tumour bed boost
17. tumor bed boost
18. sole tumour bed irradiation
19. mammosite
20. MESH DESCRIPTOR Radiotherapy, Conformal EXPLODE ALL TREES WITH QUALIFIERS AE
21. MESH DESCRIPTOR Radiotherapy, Conformal EXPLODE ALL TREES WITH QUALIFIERS MT
22. (balloon dilation):MH
23. MESH DESCRIPTOR Radiotherapy
24. OR/4-23
25. #3 AND #24
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Appendix 2. MEDLINE (Ovid) (1966 to present)
1.RANDOMIZED CONTROLLED TRIAL.pt
2. CONTROLLED CLINICAL TRIAL.pt
3. RANDOMIZED CONTROLLED TRIALS.sh
4. RANDOM ALLOCATION.sh
5. DOUBLE BLIND METHOD.sh
6. SINGLE BLIND METHOD.sh
7. or/1-6
8. (ANIMALS not HUMANS).sh
9. 7 not 8
10. CLINICAL TRIAL.pt
11. exp CLINICAL TRIALS/
12. (clin$ adj25 trial$).ti,ab
13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab
14. PLACEBOS.sh
15. placebo$.ti,ab
16. random$.ti,ab
17. RESEARCH DESIGN.sh
18. or/10-16
19. 18 not 8
20. 19 not 9
21. 9 or 20
22. exp breast neoplasms/
23. exp “neoplasms, ductal, lobular, and medullary”/
24. exp breast/
25. exp neoplasms/
26. 24 AND 25
27 (breast$ adj5 (neoplasm$ or cancer$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or dcis or ductal or infiltrat$ or
intraductal$ or lobular or medullary)).mp.
28 exp mammary neoplasms/
29 (mammar$ adj5 (neoplasm$ or cancer$ or tumo?r$ or carcinoma$ or adenocarcinoma$ or sarcoma$ or dcis or ductal or infiltrat$
or intraductal$ or lobular or medullary)).mp
30. or/22, 23,26-29
31. partial breast irradiation.sh,kw,ti,ab
32. partial breast.sh,kw,ti,ab
33. whole breast irradiation.sh,kw,ti,ab
34. whole breast radiotherapy.mp
35. less than whole breast rad$.mp
36. brachytherapy.sh,kw,ti,ab
37. high-dose-rate brachytherapy.sh,kw,ti,ab
38. accelerated partial breast irradiation.sh,kw,ti,ab
39. tumour bed boost.sh.kw.ti.ab
40. sole tumour bed irradiation.sh,kw,ti,ab
41. MammoSite.sh.kw.ti.ab
42. Breast Neoplasms/ rt.sh
43. Radiotherapy, Conformal/adverse events.sh
44. Radiotherapy, Conformal/methods.sh
45. Brachytherapy.sh
46. Balloon dilation.sh
47. Radiotherapy/.sh
48. or/31-47
49. 48 AND 30
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50. 49 AND 21
Appendix 3. EMBASE
1. randomised AND controlled AND trial
2. controlled AND clinical AND trial
3. randomi*ed:ab
4. placebo:ab
5. randomly:ab
6. trial:ab
7. groups:ab
8. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
9. ’breast’/exp AND ’neoplasm’/exp
10. locally AND advance* NEAR/6 breast AND cancer*
11. locally AND advance* NEAR/6 breast AND neoplas*
12. locally AND advance* NEAR/6 breast AND carcinoma*
13. locally AND advance* NEAR/6 breast AND tumour*
14. locally AND advance* NEAR/6 breast AND tumor*
15. early NEAR/6 breast AND cancer*
16. early NEAR/6 breast AND neoplas*
17. early NEAR/6 breast AND carcinoma*
18. early NEAR/6 breast AND tumour*
19. early NEAR/6 breast AND tumor*
20. #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR $18 OR $19
21. ‘radiotherapy’/exp OR radiotherapy
22. ‘adjuvant’/exp OR adjuvant AND (‘radiotherapy’/exp OR radiotherapy)
23. ‘radiation/exp OR radiation AND (‘therapy’/exp OR therapy)
24. #21 OR #22 OR #23
25. #8 AND #20 AND #24
Appendix 4. CINAHL
1. MH Clinical Trials
2. PT Clinical Trial
3. TX clini* n1 trial*
4. TX ((singl* n1 blind*) or (singl* n1 mask**))
5. TX randomi* control* trial*
6. MH random assignment
7. TX random* allocat*
8. TX placebo*
9. MH “Placebos”
10. MH Quantitative Studies
11. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
12. MH breast neoplasms
13. TI breast cancer OR SU breast cancer OR AB breast cancer
14. TI breast tumour OR SU breast tumour OR AB breast tumour
15. MM “Carcinoma, Ductal, Breast”
16. #12 OR #13 OR #14 OR #15
17. MM “radiotherapy, Conformal/AE”
18. MM “radiotherapy, Conformal/methods”
19. SU partial breast OR TI partial breast OR AB partial breast
20. SU whole breast irradiation OR TI whole breast irradiation OR AU whole breast irradiation
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21. SU whole breast radiotherapy
22. SU whole breast rad$ OR TI whole breast rad$ OR AB whole breast rad$
23. SU brachytherapy OR TI brachytherapy OR AB brachytherapy
24. MH brachytherapy
25. MH radiotherapy
26. SU whole breast radiotherapy OR TI whole breast radiotherapy OR AB whole breast radiotherapy
27. SU high-dose-rate brachytherapy OR AB high-dose-rate brachytherapy OR TI high-dose-rate brachytherapy
28. SU accelerated partial breast irradiation OR TI accelerated partial breast irradiation OR AB accelerated partial breast irradiation
29. SU tumour bed boost OR TI tumour bed boost OR AB tumour bed boost
30. SU MammoSite OR TI MammoSite OR AB MammoSite
31. MH “Breast Neoplasms+/RT”
32. #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31
33. #11 AND #16 AND #32
Appendix 5. Current Contents
1. TS = clinical trial*
2. TS = research design
3. TS = comparative stud*
4. TS = evaluation stud*
5. TS = controlled trial*
6. TS = follow-up study
7. TS = prospective stud*
8. TS = random*
9. TS = placebo
10. TS = single blind*
11. TS = double blind*
12. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11
13. TS = breast cancer
14. TS = breast neoplasms
15. #12 OR #13
16. TS = partial breast irradiation
17. TS = whole breast irradiation
18. TS = less than whole breast
19. TS = brachytherapy
20. TS = tumour bed boost
21. TS = Mammosite
22. #15 OR #16 OR #17 OR #18 OR #19 OR #20
23. TS = radiotherapy
24. TS = radiation therapy
25. #22 OR #23
26. #12 AND #21 AND #24
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Appendix 6. WHO ICTRP search portal
Basic search:
1. Partial irradiation for early breast cancer
2. Early breast cancer AND partial irradiation
3. Early breast cancer AND partial breast irradiation
4. Early breast cancer AND Mammosite
5. Early breast cancer AND Intracavitary brachytherapy
6. Early breast cancer AND Interstitial brachytherapy
7. Early breast cancer AND accelerated partial breast irradiation
8. Early breast cancer and less than whole breast radiotherapy
Advanced search:
1. Title: Partial irradiation for early breast cancer
Recruitment status: all
2. Condition: early breast cancer
Intervention: partial breast irradiation OR Mammosite OR intracavitary brachytherapy OR interstitial brachytherapy OR accelerated
partial breast irradiation OR less than whole breast radiotherapy
Recruitment status: all
Appendix 7. ClinicalTrials.gov
Basic searches:
1. Partial irradiation for early breast cancer
2. Early breast cancer AND partial irradiation
3. Early breast cancer AND partial breast irradiation
4. Early breast cancer AND Mammosite
5. Early breast cancer AND Intracavitary brachytherapy
6. Early breast cancer AND Interstitial brachytherapy
7. Early breast cancer AND accelerated partial breast irradiation
8. Early breast cancer and less than whole breast radiotherapy
Advanced searches:
1. Search terms: Partial irradiation for early breast cancer
Recruitment: All studies
Study type: All studies
Gender: All studies
2. Condition: Early breast cancer
Intervention: Partial breast irradiation OR Mammosite OR intracavitary brachytherapy OR interstitial brachytherapy OR accelerated
partial breast irradiation OR less than whole breast radiotherapy
Recruitment: All studies
Study type: All studies
Gender: All studies
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Appendix 8. OpenGrey
1. (breast cancer OR breast neoplasm* OR breast adenocarcinoma) AND (radiation OR irradiation OR radiotherapy OR radio-
therapy))
WH A T ’ S N E W
Last assessed as up-to-date: 4 May 2015.
Date Event Description
5 May 2015 New search has been performed Performed search for new studies on 4 May 2015
4 May 2015 New citation required but conclusions have not changed Five new studies were included, adding 5333 participants.
An additional 2 ’ongoing studies’ have been identified
H I S T O R Y
Protocol first published: Issue 2, 2008
Review first published: Issue 6, 2014
Date Event Description
15 May 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
ML, BH and DF wrote the protocol.
BH extracted data, created ’Risk of bias’ tables and ’Characteristics of included studies’ tables, analyzed the data, wrote the results
section and discussion, and responded to editorial and peer review (in consultation with ML).
ML checked the analyses, ’Risk of bias’ tables, collaborated with writing the results, discussion and conclusion sections.
AS checked the extracted data and ran the search strategy.
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D E C L A R A T I O N S O F I N T E R E S T
MH: none known.
BH: none known.
DF: none known.
AS: none known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Princess Alexandra Cancer Collaborative Group, Australia.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We reported time-to-event data where possible for cancer-related outcomes. We reported local relapse-free survival (LR-FS) rather than
local relapse (LR), distant metastasis-free survival (DM-FS) rather than distant metastases (DM), we reported loco-regional relapse-free
survival (L-R R-FS) rather than loco-regional control (LRC) as a secondary endpoint. We added the words “elsewhere primary” to the
name of the endpoint “new primary in ipsilateral breast” because this term is used in the relevant literature, in order to add clarity for
the reader.
We initially indicated that we would convert doses to their biological equivalent (BED), but have in fact used equivalent dose in 2 Gy
fractions (EQD2 ). This allows numerical addition of separate components of a treatment and is more readily understood by clinical
radiation oncologists because it results in numbers which can be directly related to clinical experience.
We added APBI as well as PBI: modern RT techniques that reduce the treated volume allow the use of high dose per fraction to the
smaller treated volume. The ongoing studies tend to use APBI, which reflects modern RT practice, making the review results more
applicable.
We added blinding to assessment of risk of bias, because the lack of blinding for the primary outcome of cosmesis would be a significant
cause of bias. We searched an additional database (i.e. EMBASE.com) and trial registry (WHO ICTRP) to our search strategy, and also
handsearched other resources. This ensured that our searches were as comprehensive as possible, and complied with Cochrane search
requirements.
We included studies which included women with ductal carcinoma in situ (RAPID) for reporting of toxicity endpoints. ELIOT used
regional nodal irradiation for those women with more or more involved nodes (5% of the cohort), we excluded ELIOT from the
analysis of L-RR-FS.
We pooled the studies in a quantitative meta-analysis, but excluded the older studies, which used surgical, RT and systemic management
practices which do not reflect current practice. We had planned sensitivity analysis based on excluding studies which used outmoded
RT and surgical techniques, but as we decided to exclude them from our analysis, we did not do so. These studies were included in the
previous iteration of this review, but were removed for the 2015 update.
We corrected the list and table of excluded studies so we are now compliant with MECIR guidelines, so that this list only includes
studies that might reasonably be expected to be included, but which we deemed ineligible.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Breast [radiation effects]; Breast Neoplasms [pathology; ∗radiotherapy; surgery]; Combined Modality Therapy [methods]; Disease-
Free Survival; Dose Hypofractionation; Mastectomy, Segmental; Neoplasm Recurrence, Local [prevention & control]; Organ Sparing
Treatments [∗methods]; Radiotherapy [adverse effects; methods]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans
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